

09/12/2024

# EU INNOVATION ECOSYSTEM ON CHRONIC INFLAMMATION & HEALTH-TO-DISEASE TRANSITION

WP7, TASK 7.3

DELIVERABLE VERSION:

D7.3, V1.0

DISSEMINATION LEVEL:

PU

AUTHOR(S):

Lena Schleicher (SEZ)

ENDOTARGET

*i*PU = Public - fully open

SEN = Sensitive - limited under the conditions of the Grant Agreement

EU classified –RESTREINT-UE/EU-RESTRICTED, CONFIDENTIEL-UE/EU-CONFIDENTIAL, SECRET-UE/EU-SECRET under Decision 2015/444

## DOCUMENT HISTORY

<b>Project Title</b>	Systemic Endotoxemia as the driver of chronic inflammation - Biomarkers and novel therapeutic targets for Arthritis	
<b>Grant Agreement N°</b>	101095084	
<b>Project Coordinator</b>	HUS	
<b>Project Duration</b>	01.01.2023 – 31.12.2026	
<b>Deliverable No.</b>	D7.3	
<b>Diss. Level</b>	Public	
<b>Deliverable Lead</b>	SEZ	
<b>Status</b>	Working	
	Verified by other WPs/Partners	
	X	Final version
<b>Due date</b>	31/12/2024	
<b>Submission date</b>	09/12/2024	
<b>Work Package</b>	WP7	
<b>Work Package Lead</b>	SEZ	
<b>Contributing beneficiary(ies)</b>	All partners	
<b>DoA</b>	This deliverable provides a map of stakeholders relevant for the ENDOTARGET project and proposes engagement activities.	

DATE	VERSION	AUTHOR	COMMENT
26/09/2024	0.1	Lena Schleicher (SEZ)	First draft
30/10/2024	0.2	Lena Schleicher (SEZ)	Second draft
31/10/2024	0.3	Lena Schleicher (SEZ)	Thrid draft
04/11/2024	0.4	Lena Schleicher (SEZ)	Fourth draft
07/11/2024	0.5	Meike Reimann (SEZ)	Fifth draft
11/11/2024	0.6	Lena Schleicher (SEZ)	Sixth draft
12/11/2024	0.7	Lena Schleicher (SEZ)	Seventh draft
20/11/2024	0.8	Lena Schleicher (SEZ)	Eighth draft
28/11/2024	0.9	Lena Schleicher (SEZ)	Ninth draft
05/12/2024	0.10	Ana Valkama, Kari Eklund, Goncalo Barreto (HUS)	Tenth draft
09/12/2024	1.0	Lena Schleicher (SEZ)	Final version

©2023–2026 ENDOTARGET Consortium Partners. All rights reserved.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authorities can be held responsible for them.

ENDOTARGET is a Horizon Europe project supported by the European Commission under grant agreement No 101095084 and it is supported by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 22.00462. All information in this deliverable may not be copied or duplicated in whole or part by any means without express prior agreement in writing by the ENDOTARGET partners. All contents are reserved by default and may not be disclosed to third parties without the written consent of the ENDOTARGET partners, except as mandated by the Grant Agreement with the European Commission, for reviewing and dissemination purposes. All trademarks and other rights on third party products mentioned in this document are acknowledged and owned by the respective holders. The ENDOTARGET consortium does not guarantee that any information contained herein is error-free, or up-to-date, nor makes warranties, express, implied, or statutory, by publishing this document. For more information on the project, its partners and contributors, please see the ENDOTARGET website ([www.endotargetproject.eu](http://www.endotargetproject.eu)).

Methods and strategies described in this deliverable D7.3 are available templates and best practices from Steinbeis2i GmbH and therefore they are replicable by their nature. Thus, the drafting of this deliverable has been inspired by similar deliverables of the projects EcoDalli (101093908), PrAEctiCe (101084248) and BioFibreLoop (101130603). Please note that Steinbeis2i GmbH is the author of the aforementioned deliverables.

## EXECUTIVE SUMMARY

This deliverable reports on the mapping of relevant stakeholders on local, regional, and European levels, which was done by the consortium throughout the first half of the project. In addition, the consortium identified possible key stakeholders and discussed suitable engagement activities, which have already been implemented (D7.5, M24) or will be implemented during the second half of the project as needed.

This stakeholder map will facilitate the identification and engagement of key stakeholders throughout the project to (i) fine-tune the project's methodological approach to ensure that results are sufficiently tailored to the different stakeholder groups and to (ii) guide and advise the consortium considering exploitation of the results.

This deliverable represents the final report of task 7.3 "Stakeholder engagement", which ends in M24. Simultaneously, with this deliverable the project will reach Milestone 08 "Mapping of stakeholders in CI and health-to-disease transition".

# TABLE OF CONTENT

## Contents

- Document History ..... 2
- Executive Summary..... 5
- Table of content ..... 6
- List of Tables..... 7
- List of Figures..... 7
- List of Abbreviations..... 7
- 1. Introduction..... 9
  - 1.1. ENDOTARGET and the ecosystem .....11
- 2. Methodology .....12
  - 2.1 Stakeholder Mapping .....12
  - 2.2 Key Stakeholder Identification..... 15
  - 2.3 Stakeholder Contact and Engagement approach..... 15
- 3. Result .....17
  - 3.1 Categorisation.....17
  - 3.2 Stakeholder Mapping ..... 19
  - 3.3 identification of and engagement with key stakeholders ..... 19
- 4. Conclusion..... 26
- 5. Annex.....27

## LIST OF TABLES

Table 1. Information about stakeholders collected with the MS Teams list .....12  
 Table 2. Stakeholder engagement approach..... 15  
 Table 3. List of identified key stakeholders for the ENDOTARGET project..... 20  
 Table 4. Summary of all collected stakeholders by M24 .....27

## LIST OF FIGURES

Figure 1. Important elements of the EU innovation ecosystem on chronic inflammation & health-to-diseases transition..... 10  
 Figure 2. Stakeholder engagement in EU project based on stakeholder role and project timeline..... 15  
 Figure 3. Categories of ENDOTARGET stakeholders.....17  
 Figure 4. Number of all identified stakeholders in the categories R&D, End Users, (public) Authorities and Industry. Red: Number of stakeholders to which the consortium has direct contact; Blue: Number of stakeholders to which the consortium has no direct contact so far. .... 19

## LIST OF ABBREVIATIONS

ACRONYM	DESCRIPTION
AI	Artificial intelligence
CI	Chronic inflammation
D	Deliverable
DC	Dissemination, Communication
DCE	Dissemination, Communication, Exploitation

EU	European Union
FMT	Fecal Microbiota Transplantation
H2020	Horizon 2020
HE	Horizon Europe
HTA	Health Technology Assessment
HUS	Helsinki University Hospital
IA	If applicable
LPS	Lipopolysaccharides
M	Month
OA	Osteoarthritis
RA	Rheumatoid Arthritis
RD	Rheumatic disease
RDPT	Rheumatic Disease risk Prediction Tool
R&D	Research and Development
SEZ	Steinbeis 2i GmbH
SpA	Spondylarthritis
WP	Work Package

# 1. INTRODUCTION

Chronic inflammatory diseases are the leading cause of mortality worldwide, responsible for 3 out of 4 deaths.<sup>1</sup> Chronic inflammation (CI) is a prolonged and persistent inflammatory response in the body that can last for months or even years. Unlike acute inflammation, which is a short-term and beneficial response to injury or infection, CI can have detrimental effects on tissues and organs. The clinical consequences of a CI can be severe and include increased risk of diabetes, cardiovascular diseases, arthritis & joint diseases, allergies, and chronic obstructive pulmonary disease.

The prevention and treatment of CI and its associated diseases is only possible to a limited extent, as the underlying complex biological mechanisms are often not yet understood. Thus, there is a tremendous need for new and effective innovations to overcome this challenge.

The **EU innovation ecosystem on CI and health-to-disease transition** refers to a network that brings together diverse stakeholders to collaboratively address the complexities of CI and the transition from a healthy state to disease on a European level. This ecosystem aims to facilitate research, development, and implementation of innovative solutions to manage and treat these conditions. More precisely, the ecosystem aims to:

1. Enhance the scientific understanding of CI and disease mechanisms
2. Develop effective and personalised treatment therapies and diagnostic tools to prevent, manage, and treat CI and its associated diseases
3. Improve the quality of life and health outcomes for patients in CI conditions
4. Promote sustainable healthcare practices and reduce the burden of chronic diseases on healthcare systems

For a functioning CI ecosystem, diverse stakeholders have to interact, including: (i) **Research and Development** facilities to conduct fundamental and applied research and to develop new scientific knowledge & technologies, (ii) **Healthcare providers** implementing and testing new therapeutic approaches, (iii) **Industrial** stakeholders for developing & commercialising new technologies and products (drugs, digital health solutions, etc.), (iv) **Public and Private Funding Agencies** to provide financial support for research and innovation projects and to foster public-private

---

<sup>1</sup> Pahwa R, Goyal A, Jialal I. Chronic Inflammation. [Updated 2023 Aug 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK493173/>

partnerships, (v) **Regulatory Bodies** to ensure that new treatments and technologies are safe & effective and to create new/ improved policies & guidelines, (vi) **Patient Organisations and Advocates** to represent patient interests & needs and to participate in the design & evaluation of research, (vii) **Policymakers and Public Authorities** to formulate health policies that promote research and to ensure a supportive regulatory environment (Figure 1).




Figure 1. Important elements of the EU innovation ecosystem on chronic inflammation & health-to-diseases transition.

The establishment and maintenance of this ecosystem are of particular importance to all stakeholders, as a functioning ecosystem offers many benefits:

- It fosters partnerships among stakeholders and enables multidisciplinary research and development.
- It secures financial resources for innovation projects and encourages investments in promising technologies. By attracting funding and investment, the ecosystem ensures that cutting-edge research and development efforts are adequately supported.
- It facilitates the transfer of knowledge and technology, as well as the commercialisation of new treatments and technologies. This ensures that breakthroughs in research are efficiently translated into practical applications.
- It promotes data sharing among stakeholders. Effective data sharing is key to advancing research, improving clinical outcomes, and driving innovation in healthcare.
- It drives the development of new diagnostics, therapies, and preventive measures, as well as the adoption of innovative healthcare solutions. This leads to improved patient care and better health outcomes.

- It ensures the development and implementation of standards and guidelines, as well as compliance with regulatory requirements. By adhering to these standards, the ecosystem maintains high-quality and safe healthcare practices.
- It involves patients in research and treatment designs, ensuring that their needs are addressed. Patient involvement is vital for creating treatments and healthcare solutions that are truly patient-centred and effective.

## 1.1. ENDOTARGET AND THE ECOSYSTEM

The ENDOTARGET project explores the role of CI caused by intestinal microbiota-derived immunologically active compounds as a driver in the transition from health-to-disease with a special focus on three rheumatic diseases: osteoarthritis (OA), rheumatoid arthritis (RA), and spondylarthritis (SpA). The aim is to gain new insights into the relationship between gut microbiota, intestinal permeability, and systemic endotoxemia (refers to the systemic circulation of microbiota-derived immunologically active compounds in the body). Further, ENDOTARGET aims to understand this relationship in the context of disease onset and disease activity in RA, SpA, and OA, as well as targets of preventive and therapeutic approaches.

In order to support the project's impact maximisation, the translation of project outputs into clinical practice, and the provision of new solutions to the market, the ENDOTARGET consortium has to engage and collaborate with stakeholders of the CI and health-to-disease transition ecosystem. Therefore, several activities throughout the project are needed, including dissemination & communication (D7.1, D7.5) and exploitation support (D7.4).

This deliverable reports on task 7.3 "stakeholder engagement" of WP7 and contributes to the completion of Milestone 08 "Mapping of stakeholders in CI and health-to-disease transition" (M24). This task aims to provide a stakeholder mapping of relevant partners on local, regional, and European levels for networking and liaising activities, which will be used in ENDOTARGET to leverage the project's dissemination and exploitation strategy. Identified key stakeholders were already contacted or will be consulted in the further course of the project to fine-tune the project's methodological approach, ensuring that results are sufficiently tailored to the different stakeholder groups, and to guide & advise the consortium considering exploitation of the results. The stakeholder map simultaneously acts as a contact database, which serves as a project's internal tool to systematically collect all relevant information about the stakeholder.

## 2. METHODOLOGY

Task T7.3 “stakeholder engagement” includes (i) the mapping of the stakeholder ecosystem on CI & health-to-disease transition, (ii) the identification of key stakeholders, and (iii) the contacting and engaging with key stakeholders throughout the project.

The following sections are structured according to the main stages carried out in this task. It describes the process of stakeholder identification following predefined categories. The collected data was revised to determine (possible) key stakeholders and define suitable engagement activities.

### 2.1 STAKEHOLDER MAPPING

Before stakeholder mapping was carried out, the consortium agreed on four main stakeholder categories, which include all relevant stakeholder groups in the CI and health-to-disease transition ecosystem. According to them, the identification and collection of relevant stakeholders for the ENDOTARGET project was carried out with the collaboration of all project partners. On the one hand, suitable stakeholders, which are already present in the partner network, were collected. On the other hand, SEZ did online research to find further stakeholders, using, e.g., the CORDIS database, social media, and events. The information was collected through an MS Teams list accessible to all partners on the ENDOTARGET Teams platform. With this list, the following information was collected (Table 1):

Table 1. Information about stakeholders collected with the MS Teams list

Information Type	Options
Partner responsible for entry	Free text
Name of Stakeholder	Free text
Acronym (IA)	Free text
Website link (IA)	Free text
Type of Organisation (4 main stakeholder categories)	<p><b>R&amp;D</b></p> <ul style="list-style-type: none"> <li>• Academic institutions/ Universities</li> <li>• R&amp;D institution/ centers</li> <li>• Research Associations/ Foundations</li> <li>• (EU) Projects</li> <li>• Cohort/ Biobank</li> </ul> <p><b>Industry</b></p>

	<ul style="list-style-type: none"> <li>Pharma</li> <li>Engineering &amp; MedTech</li> <li>Service Providers</li> <li>Industrial Association</li> <li>Food/ Nutrition</li> </ul> <p><b>Authorities</b></p> <ul style="list-style-type: none"> <li>Regional/National/International Authorities and regulatory bodies</li> <li>Professional Associations</li> <li>Educational Authority</li> <li>Health Services &amp; Funds</li> <li>Funding Agencies &amp; Entities Supporting Research</li> </ul> <p><b>End Users</b></p> <ul style="list-style-type: none"> <li>Citizens</li> <li>Network/ Patient Associations</li> <li>Clinicians/ Clinics</li> <li>Other Healthcare Workers</li> </ul>
Sector/ Topic	<ul style="list-style-type: none"> <li>Chronic inflammation</li> <li>Rheumatic diseases</li> <li>Microbiome</li> <li>Gastroenterology</li> <li>Organ-on-a-chip</li> <li>Biomarkers</li> <li>Policy</li> <li>AI</li> <li>Health care</li> <li>Research</li> <li>Clinical trials</li> <li>Digital health solutions</li> <li>Cohort/ study</li> <li>Engineering &amp; Biotechnology</li> <li>Animal Models</li> <li>Nutrition</li> <li>Other</li> </ul>
Geographic Scope	<ul style="list-style-type: none"> <li>National</li> <li>Regional</li> <li>European</li> <li>International</li> </ul>
Country	Free text
Influence	<ul style="list-style-type: none"> <li>High</li> <li>Medium</li> <li>Low</li> </ul>
Possible Role in ENDOTARGET	<ul style="list-style-type: none"> <li>User</li> <li>Enabler/ Multiplier</li> <li>Developer</li> </ul>

---

	<ul style="list-style-type: none"> <li>• Observer</li> </ul>
Joint activity	Free text

---

If any contact information (e.g., eMail addresses) was collected, it is publicly available data, which can be found through search engines and is published via different websites and documents. In addition, identification and collection of relevant stakeholders were always discussed during consortium or WP7 meetings.

An important task when compiling the stakeholders was to assign them possible roles in the project. A distinction was made between **User** (makes use of the project’s output), **Enabler** (can help to facilitate project activities), **Developer** (is interested in helping to co-produce and shape the project outputs), and **Observer** (is interested in the subject matter of the project but might not want to get directly involved).

In the course of a research project, there is a rough principle as to *when* and *why* each stakeholder should be involved in the project based on the stakeholder role (Figure 2): At the beginning of a project, the consortium has to build up collaborations with Enablers, e.g., patient associations, societies, or foundations, that have a big network & audience and support the project in disseminating and communicating their project activities & news. Further, these stakeholders can help the consortium leverage their outreach, including new audiences. Next to Enablers, the consortium has to collaborate with Developers, e.g., R&D stakeholders or other (EU) projects. They can support the project with scientific activities to produce and shape the project outputs. This way, the consortium might get new ideas and can receive advice from other experts. As soon as the first results are obtained, the consortium has to collaborate with Users, e.g., clinicians, patients and citizens, that make use of and test the preliminary project outputs. Their feedback is highly important in order to adapt the result to their needs. Afterwards, collaboration with Enablers are again very useful to communicate and disseminate the project results widely. Towards the end of the project, engagement with Users and Observers, e.g., policy makers and authorities, is important to get support in reaching the project impact and in realising the exploitation plans.




Figure 2. Stakeholder engagement in EU project based on stakeholder role and project timeline.

## 2.2 KEY STAKEHOLDER IDENTIFICATION

In the second half of 2024, each partner received a draft of the stakeholder map for revision. In addition, each partner was asked to select their 5 most important stakeholders per category. This way, key stakeholders for the project were identified and will be prioritised for engaging, if not already done.

## 2.3 STAKEHOLDER CONTACT AND ENGAGEMENT APPROACH

Depending on the stakeholder, the consortium will make contact via the developed eMail template or use existing contact between ENDOTARGET partners and the stakeholders.

The consortium has elaborated on different opportunities on how to engage with its stakeholders, depending on their role for the project (Table 2):

Table 2. Stakeholder engagement approach.

Engagement Approach	Example of Action
Communicate	<ul style="list-style-type: none"> <li>• Social Media &amp; ENDOTARGET Website</li> <li>• Webinar</li> <li>• (scientific) Publications</li> <li>• Press releases</li> <li>• Symposium or conference</li> </ul>
Advocate	<ul style="list-style-type: none"> <li>• Bilateral meetigs</li> </ul>

Consult	<ul style="list-style-type: none"> <li>• Surveys</li> <li>• Targeted interviews</li> </ul>
Collaborate & co-create	<ul style="list-style-type: none"> <li>• Bilateral meetings</li> <li>• Roundtables</li> <li>• Workshops</li> <li>• Peer-to-peer learning sessions</li> <li>• Site visits</li> <li>• Use of services</li> </ul>

**Communicate:** The communication approach aims to ensure that all stakeholders receive clear and accessible information about the objectives, progress, and outcomes of the ENDOTARGET project in order to build and maintain trust. To this end, regular progress reports, newsletters, and updates are published on social media or sent directly to stakeholders to provide them with detailed information on the project's milestones, successes, and challenges. In addition, the ENDOTARGET consortium will maintain its website with comprehensive project documentation. ENDOTARGET'S communication approaches are described in detail in D7.1 (1<sup>st</sup> version of Dissemination and Communication plan), D7.2 (ENDOTARGET project website) and D7.5 (2<sup>nd</sup> version of Dissemination and Communication plan).

**Advocate:** To advocate is especially important when engaging with stakeholders who have a high influence but show low interest in getting directly involved in the project (Observer). Thus, a strategic approach is essential to raise awareness and generate interest so that they are convinced to actively participate in the project and to support it. The project partners will plan and implement the following activities to achieve this objective:

- Provision of tailored information that emphasises the stakeholders benefits of the project and that the project is directly aligned with its priorities.
- Creation of direct, personal connections through meetings and one-on-one discussions, providing exclusive opportunities for involvement.
- Initiation of advocacy efforts aimed at raising awareness and gaining support for the project by highlighting concrete project impacts and seeking feedback for ongoing improvement.

**Consult:** Consultation activities represent bidirectional activities where an exchange between stakeholders and the ENDOTARGET consortium takes place. For example, selected stakeholders will actively participate in consultations to provide insights into their interests and to identify perceived gaps, challenges, and opportunities related to ENDOTARGET solutions. Possible consult activities are surveys and targeted interviews to solicit feedback or input for, e.g., a project result.

**Collaborate and co-create:** Collaboration and co-creation activities will be conducted with highly relevant and interested stakeholders. The goal is to pave the way for demand-driven ENDOTARGET solutions and results. Engagement activities will be implemented as needed, e.g., bilateral meetings, roundtables, workshops, peer-to-peer learning sessions, site visits, use of services.

### 3. RESULT

#### 3.1 CATEGORISATION

At the beginning of the project, the consortium partners agreed on four main stakeholder categories, with sub-categories, which include all relevant stakeholder groups in the CI and health-to-disease transition ecosystem: End Users, Research & Development, (Public) Authorities, and Industry (Figure 3).




Figure 3. Categories of ENDOTARGET stakeholders.

## Industry

Stakeholders in the category “Industry” are, e.g., service providers, engineering & MedTech companies, food & nutrition companies/producers, industrial associations, and pharmaceutical companies. They might become important for the exploitation of project results by, e.g., supporting the further development and commercialisation/market deployment of project results.

## R&D

The EDNOTARGET project will provide new insights into the mechanism involved in arthritis pathogenesis and the health-to-disease transition, which is also relevant for other R&D actors working in the field of CI, such as research associations and foundations, other (EU) projects, study cohorts and biobanks, research institutions & centres, and academic institutions.

Through collaborative activities, a mutual transfer of knowledge is achieved, and new partnerships are initiated, leading to multidisciplinary research and development, which is needed to tackle the complexity of CI. This way, these stakeholders have the opportunity to shape and co-develop the project results, and vice versa, to obtain new findings and to develop new technologies and treatments.

## (Public) Authorities

Public authorities comprise authorities on regional, national, and international levels. Their commitment is needed to develop new standards and guidelines, as well as to implement new health policies in clinical practice. Their support is needed to successfully formulate new clinical and policy recommendations, as well as for the implementation of the RDPT. The collaboration with regulatory bodies (e.g., HTA) is also essential since they are the authorities ensuring and judging that a new treatment or technology is safe and effective and recommending them for use in clinical practice. They also provide regulatory support for the implementation of new technologies and treatments. Next to this, these authorities might also provide financial support for further research and development.

## End users

End users comprise a wide range of possible users or interested parties in the processes fostered by ENDOTARGET. Healthcare providers (clinicians, healthcare workers) are not only the users of the developed diagnostic and therapeutic approaches but are also needed in the development process. They test the new approaches and collect clinical data for further research and development.

Patients and patient associations are a very important stakeholder group since they will also be users of the new diagnostic and therapeutic approaches, and they are the ones benefiting the most from their implementation in clinical practice.

### 3.2 STAKEHOLDER MAPPING

The stakeholder mapping process involved the identification and analysis of various stakeholders within the regional and European landscape that can influence the ENDOTARGET project as well as those that can benefit from it. This task addresses both the strategic dissemination and exploitation of project outcomes, as well as the facilitation of synergistic collaborations.

Thus, the consortium first focused on identifying a broad range of different stakeholders according to the target groups, i.e. End Users, Research & Development, (public) Authorities, and Industry.

This map identifies in total 426 stakeholders with the following distribution: 161 for R&D, 79 for End Users, 111 for (public) Authorities, and 75 for Industry. Out of these 426, the consortium has direct contact with 170 of them (91 R&D, 30 End Users, 36 (public) Authorities, 13 Industry) (Figure 4).




Figure 4. Number of all identified stakeholders in the categories R&D, End Users, (public) Authorities and Industry. Red: Number of stakeholders to which the consortium has direct contact; Blue: Number of stakeholders to which the consortium has no direct contact so far.

### 3.3 IDENTIFICATION OF AND ENGAGEMENT WITH KEY STAKEHOLDERS

Key stakeholders refer to stakeholders that (i) have a lot of influence over the development of ENDOTARGET, (ii) are directly affected by its results and outcomes, (iii) are or might become crucial for the further development of the project, or (iv) are or might become crucial for the project's exploitation.

During the first half of the project, consortium partners were already in contact with key stakeholders, which helped them during the first phase of the project, especially in DC and the research process D7.5 (2<sup>nd</sup> version of Dissemination and Communication plan). As the project progresses, the consortium will regularly discuss with whom engagement activities should be carried out to ensure successful dissemination and exploitation of the project results.

In the following Table 3, the identified key stakeholders are listed (all identified stakeholders can be found in the annex, Table 4):

Table 3. List of identified key stakeholders for the ENDOTARGET project.

Stakeholder Name	WHY key stakeholder?	Role*	Contact established?	Possible Engagement Approach*
<b>R&amp;D</b>				
<a href="#">University of Naples Federico II, Department of Chemical Sciences</a>	Strong expertise in analysing LPS structures	Developer	Yes	Collaborate
<a href="#">University of Helsinki, Functional Genomics Unit</a>	Core facility has strong expertise in sequencing	Developer	Yes	Collaborate, use of service
<a href="#">University of Helsinki, Institute of Biotechnology, DNA sequencing and genomics</a>	Core facility has strong expertise in sequencing	Developer	Yes	Collaborate, use of service
<a href="#">The European Fecal Microbiota Transplantation Network of academics</a>	High influence; support in DCE, esp. in the formulation of new FMT recommendations	Enabler, Observer	Yes	Co-create, advocate
<a href="#">Osteoarthritis Research Society International</a>	High influence; support in DCE	Enabler	No	Communicate, advocate, co-create
<a href="#">International Cartilage Regeneration &amp; Joint Preservation Society</a>	High influence; support in DCE	Enabler	Yes	Communicate
<a href="#">Arthritis National Research Foundation</a>	Provision of further funding	Enabler	No	Advocate
<a href="#">Arthritis checkup</a>	Collaboration by e.g., sharing human samples	Developer	No	Collaborate
<a href="#">Microbiota and Mucosal Barrier Research in Rheumatic and Musculoskeletal Diseases EULAR study group</a>	High influence; support in DCE; sharing of knowledge and expertise	Enabler, Developer	Yes	Advocate, consult, collaborate
<a href="#">EULAR Study Group on Social Media for Rheumatology Healthcare Professionals</a>	Support in DCE	Enabler	No	Advocate, consult, collaborate
<a href="#">The Genetics of Osteoarthritis</a>	Will benefit from the project results and is interested in (re-)using them	Enabler, End Users	No	Communicate, collaborate
<a href="#">Institute for Food &amp; Health, Germany</a>	Will benefit from the project results and is interested in (re-)using them	End User	No	Communicate, collaborate
<a href="#">GlycanTrigger</a>	Scientific collaboration	Developer	Yes	Collaborate
<a href="#">Austrian Cluster for Tissue Regeneration</a>	Strong expertise on fabrication	Developer	Yes	Collaborate

<a href="#">Advanced Microfluidics Initiative</a>	Strong expertise on fabrication	Developer	Yes	Collaborate
<a href="#">Joanneum Research</a>	Strong expertise on fabrication	Developer	Yes	Collaborate
<a href="#">CArdiovascularREsolution of INflammation to promote HEALTH</a>	Strong expertise on fabrication	Developer	Yes	Collaborate
<a href="#">University of Copenhagen, Microbiome Systems Biology</a>	Strong expertise on fabrication	Developer	Yes	Collaborate
<a href="#">Proto</a>	Scientific collaboration (e.g., validation of ENDOTARGET biomarkers)	Developer	Yes	Collaborate
<a href="#">NetwOArk</a>	High influence (research leaders in osteoarthritis in Europe); support in DCE; sharing of knowledge and expertise	Enabler, Developer	Yes	Communicate, collaborate
<a href="#">Utrecht University Medical Center, Netherlands</a>	Scientific collaboration, further research on ENDOTARGET biomarkers	Developer	Yes	Collaborate
<a href="#">University of Calgary, Canada</a>	Scientific collaboration, further research on ENDOTARGET biomarkers	Developer	Yes	Collaborate
<a href="#">Friederich Alexander Universität, Erlangen</a>	Scientific collaboration	Developer	Yes	Collaborate
<a href="#">University of Toronto, Institute of Medical Science</a>	Scientific collaboration	Developer	Yes	Collaborate
<a href="#">Queensland University, Frazer Institute</a>	Scientific collaboration	Developer	Yes	Collaborate
<a href="#">Humanitas University, Milan</a>	Scientific collaboration	Developer	Yes	Collaborate
<a href="#">Maugeri Clinical Scientific Institutes</a>	Scientific collaboration	Developer	Yes	Collaborate
<a href="#">Emerging EULAR Network</a>	Scientific collaboration	Developer	Yes	Collaborate
<a href="#">AbbVie</a>	Support in DCE	Enabler	Yes	Communicate
<b>End Users</b>				
<a href="#">Helsinki University Hospital</a>	Has an abdominal center specialised in FMT therapy which can use project results	End User	Yes	Communicate, consult, collaborate
<a href="#">Päijät-Häme Central Hospital, Lahti, Finland</a>	Has a gastroenterology unit performing FMT therapy which can use project results	End User	Yes	Communicate, consult, collaborate

<a href="#">Kuopio University Hospital</a>	Has a gastroenterology unit performing FMT therapy which can use project results	End User	Yes	Communicate, consult, collaborate
<a href="#">Finnish Rheumatism Association</a>	Patient association that is interested and can use project results	End User	No	Communicate, consult
<a href="#">Finnish Orthopaedic Association</a>	Patient association that is interested and can use project results	End User	No	Communicate, consult
<a href="#">The international OA foundation</a>	Will benefit from the project results and is interested in (re-)using them	End User	No	Communicate, collaborate
<a href="#">European Alliance for Associations for Rheumatology</a>	High influence; support in DCE	Enabler, End User	Yes	Communicate, consult, collaborate
<a href="#">EULAR People with Arthritis / Rheumatism across Europe</a>	Patient association that is interested and can use project results	End User	Yes	Communicate, consult, collaborate
<a href="#">European Personalized Medicine Association</a>	Association with high influence that is interested and can use project results	End User	No	Communicate, consult, collaborate
<a href="#">Paediatric Rheumatology European Society</a>	Patient association with high influence that is interested and can use project results	End User	Yes	Communicate, consult, collaborate
<a href="#">European Network for Children with Arthritis</a>	Patient association with high influence that is interested and can use project results	End User	Yes	Communicate, consult, collaborate
<a href="#">Liga Portuguesa contra as Doenças Reumáticas</a>	Patient association with high influence that is interested and can use project results	End User	Yes	Communicate, consult, collaborate
<a href="#">Associação Nacional de Doentes com Artrites e Reumatismos da Infância</a>	Patient association with high influence that is interested and can use project results	End User	Yes	Communicate, consult, collaborate
<a href="#">Sociedade Portuguesa de Reumatologia</a>	Patient association with high influence that is interested and can use project results	End User	Yes	Communicate, consult, collaborate
<a href="#">Austrian Society for Orthopaedics and Orthopaedic Surgery</a>	Patient association with high influence that is interested and can use project results; collection of end user impressions/feedback	End User	No	Communicate, consult
<a href="#">Physio Austria</a>	Patient association with high influence that is interested and can use project results; collection of end user impressions/feedback	End User	No	Communicate, consult

<a href="#">Austrian Society for Geriatrics and Gerontology</a>	Patient association with high influence that is interested and can use project results; collection of end user impressions/feedback	End User	No	Communicate, consult
<a href="#">Hey OAI Podcast</a>	Support in DCE	Enabler	Yes	Communicate
<a href="#">Patients network for medical research and health</a>	Patient association with high influence that is interested and can use project results	End User	Yes	Communicate, consult, collaborate
<a href="#">Assessment of SpondyloArthritis international Society</a>	International group of experts who is interested in the project results; support in DCE	End User, Enabler	Yes	Communicate, consult, collaborate
<a href="#">Italian Society of Rheumatology</a>	Interested in project results; support in DCE	End User, Enabler	Yes	Communicate, advocate, consult, collaborate
<a href="#">Italian Research Group in Clinical Rheumatology</a>	Scientific collaboration; support in DCE	Developer, Enabler	Yes	Communicate, collaborate
<b>(Public) Authorities</b>				
<a href="#">Research Council of Finland</a>	Provision of further funding	Observer, Enabler	Yes	Advocate
<a href="#">The Paulo Foundation, Finland</a>	Provision of further funding	Observer, Enabler	Yes	Advocate
<a href="#">NovoNordisk Foundation, Finland</a>	Provision of further funding	Observer, Enabler	Yes	Advocate
<a href="#">Päivikki and Sakari Sohlberg Foundation Finland</a>	Provision of further funding	Observer, Enabler	Yes	Advocate
<a href="#">State Secretariat for Education, Research and Innovation Switzerland</a>	Provision of further funding	Observer, Enabler	No	Advocate
<a href="#">Swiss national science foundation</a>	Provision of further funding	Observer, Enabler	No	Advocate
<a href="#">European Medicine Agency</a>	Policy maker with high influence who facilitates DCE; licensing of products/devices from the project	Observer, Enabler	Yes	Advocate, consult, collaborate
<a href="#">U.S. Food and Drug Administration</a>	Policy maker with high influence who facilitates DCE	Observer, Enabler	Yes	Advocate
<a href="#">International Network of Agencies for Health Technology Assessment</a>	Network with high influence who facilitates DCE	Observer, Enabler	No	Advocate
<a href="#">European Commission (Horizon Europe)</a>	Policy maker with high influence who facilitates DCE and provides further funding	Observer, Enabler	No	Advocate

<a href="#">Portuguese Ministry of Health</a>	Policy maker with high influence who facilitates DCE	Observer, Enabler	Yes	Advocate
<a href="#">Ordem dos Médicos</a>	National association of doctors with high influence who facilitates DCE	Observer, Enabler	Yes	Advocate, consult, collaborate
<a href="#">Austrian Federal Office for Safety un Health Care</a>	Policy maker with high influence who facilitates DCE; licensing of products/devices form the project	Observer, Enabler	No	Advocate, consult, collaborate
<a href="#">Austrian Agency for Education and Internationalisation</a>	Policy maker with high influence who facilitates DCE	Observer, Enabler	No	Advocate
<a href="#">Austrian Health Insurance Fund</a>	Policy maker with high influence who facilitates DCE; licensing of products/devices form the project	Observer, Enabler	No	Advocate, consult, collaborate
<a href="#">ON foundation</a>	Provision of further funding	Observer, Enabler	Yes	Advocate
<a href="#">Italian Medicine Agency</a>	Policy maker with high influence who facilitates DCE	Observer, Enabler	Yes	Advocate
<a href="#">The Italian National Agency for Regional Health Services</a>	Policy maker with high influence who facilitates DCE	Observer, Enabler	Yes	Advocate
<a href="#">Ministry of Health Italy</a>	Policy maker with high influence who facilitates DCE	Observer, Enabler	Yes	Advocate
<a href="#">Ministry of Education and Merit Italy</a>	Policy maker with high influence who facilitates DCE	Observer, Enabler	Yes	Advocate
<a href="#">National Health Service Italy</a>	Policy maker with high influence who facilitates DCE	Observer, Enabler	Yes	Advocate
<b>Industry</b>				
<a href="#">CSC – IT Center for Science</a>	Strong expertise in IT solutions	Enabler	Yes	Collaborate, use of service
<a href="#">Bacthera</a>	Strong expertise in next generation probiotics	Enabler	Yes	Advocate, consult, collaborate
<a href="#">The Akkermansia Company</a>	Strong expertise in next generation probiotics	Enabler	Yes	Advocate, consult, collaborate
<a href="#">International Flavors and Fragrances</a>	Strong expertise in next generation probiotics	Enabler	Yes	Advocate, consult, collaborate
<a href="#">Federación Española de Industriales Fabricantes de Aceite de Oliva</a>	Interested in (re-)using the project results	End User	No	Communicate, collaborate
<a href="#">Novartis</a>	Interested in (re-)using the project results, e.g. support in	End User	Yes	Advocate, consult, collaborate

	scaling-up for industrially relevant production or OA drug development				
<a href="#">European Federation of Pharmaceutical Industries and Associations</a>	Interested in (re-)using the project results	End User	No	Advocate, consult, collaborate	
<a href="#">Medicines for Europe</a>	Interested in (re-)using the project results	End User	No	Advocate, consult, collaborate	
<a href="#">The European Association for Bioindustries</a>	Interested in (re-)using the project results	End User	No	Advocate, consult, collaborate	
<a href="#">STRATEC</a>	Interested in (re-)using the project results, e.g. support in scaling-up for industrially relevant production	End User	No	Advocate, consult, collaborate	
<a href="#">kdg</a>	Interested in (re-)using the project results, e.g. support in scaling-up for industrially relevant production	End User	No	Advocate, consult, collaborate	
<a href="#">Institute of Entrepreneurship Development</a>	Support for exploitation, e.g. by spinning off a start-up	End User, Enabler	No	Advocate, consult, collaborate	
<a href="#">Z-Microsystems</a>	Interested in (re-)using the project results, e.g. support in scaling-up for industrially relevant production	End User	No	Advocate, consult, collaborate	
<a href="#">Johnson &amp; Johnson Innovative Medicine</a>	Interested in (re-)using the project results; support in DCE	End User, Enabler	Yes	Advocate, consult, collaborate	
<a href="#">UCB Pharma</a>	Interested in (re-)using the project results; support in DCE	End User, Enabler	Yes	Advocate, consult, collaborate	
<a href="#">Lilly</a>	Interested in (re-)using the project results; support in DCE	End User, Enabler	Yes	Advocate, consult, collaborate	
<a href="#">Novo Nordisk Pharma GmbH</a>	Interested in (re-)using the project results, e.g. OA drug development	End User	No	Advocate, consult, collaborate	

\*Definition of the stakeholder roles: User makes use of the project's output; Enabler can help to facilitate project activities; Developer is interested in helping to co-produce and shape the project outputs; Observer is interested in the subject matter of the project, but might not want to get directly involved.

+Engagement approaches: Communicate includes e.g., social media, ENDOTARGET website, webinars, (scientific) publications, press releases, symposia or conferences; Advocate influences e.g., bilateral meetings; Consult includes e.g., surveys, targeted interviews, soliciting feedback or input on a project result; Collaborate & co-create includes e.g., bilateral meetings, roundtables, workshops, peer-to-peer learning sessions, site visits, use of services.

## 4. CONCLUSION

This deliverable provides an overview of the mapping of relevant stakeholders at local, regional, and European levels, which was done by the consortium in the first half of the project and also serves as a contact database. In addition, the consortium has identified potential key stakeholders and discussed engagement strategies.

Thus, this report will support the ENDOTARGET partners in the further course of the project in finding the right stakeholders for certain project and exploitation activities and in implementing suitable engagement activities.

This way, the consortium also guarantees that the key objectives of DCE are achieved:

1. Raise awareness, ensuring project visibility via effective actions, scaling up project impact, and for the successful exploitation of project results.
2. Engage with key stakeholders, creating the conditions for effective mobilisation and engagement of end users who contribute to the project.
3. Foster outreach via effective communication of the results across Europe and the development of a large community around the project objectives.
4. Influence decision makers by sharing and transferring relevant conclusions derived from the activities and project outcomes.
5. Boost sustainability, paving the way for future exploitation through effective collaboration of stakeholders during and after the project.

## 5. ANNEX

Table 4. Summary of all collected stakeholders by M24. CI = chronic inflammation; RD = rheumatic diseases; AI = artificial intelligence. \*only applicable for possible key stakeholders.

Name	Acronym	Type of Organisation	Sector/Topic	Geographic Scope	Country	Influence	possible key stakeholder	Role*	Engagement Activity*	Direct Contact?
R&D										
<a href="#">AbbVie</a>		R&D institutions/ centers	Research	International		High	Yes	Enabler	Communicate	Yes
<a href="#">Adherence to Therapy in RMDs EULAR Study Group</a>		Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">Advanced Microfluidics Initiative</a>	AMI	Research Associations/ Foundations	Research, Engineering & Biotechnology	National	Austria	Medium	Yes	Developer	Communicate	No
<a href="#">Advanced PerOsOnalized Therapies for Osteoarthritis – TACKLING INFLAMMATION TO IMPROVE PATIENT OUTCOMES</a>	PROTO	(EU) Projects	Research, CI, RD, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	Yes	Developer	Collaborate	Yes
<a href="#">An Artificially Intelligent Diagnostic Assistant for gastric inflammation</a>	AIDA	(EU) Projects	Research, CI, Health care, AI, Digital health solutions, clinical trials, biomarkers, Gastroenterology	European		Medium	No			No

<a href="#">Arthritis Checkup</a>		Cohort/ Biobank	Research, CI, Health care, RD, Cohort/ study, Clinical study	European		Medium	Yes	Developer	Collaborate	No
<a href="#">Arthritis National Research Foundation</a>	ANRF	Research Associations/ Foundations	Research, RD, CI, policy	National	USA	High	Yes	Enabler	Advocate	No
<a href="#">Austrian Cluster for Tissue Regeneration</a>		Research Associations/ Foundations	Research, Engineering & Biotechnology, policy	National	Austria	High	Yes	Developer	Collaborate	No
<a href="#">BioKeralty Research Institute</a>		Research Associations/ Foundations	Research, Engineering & Biotechnology, Health care, Digital health solutions	National	Spain	Medium	No			No
<a href="#">Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception.</a>	PREVA-LUNG EU	(EU) Projects	Research, CI, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			No
<a href="#">BioNanoNet Association</a>	BNN	Research Associations/ Foundations	Research, Engineering & Biotechnology	European		Medium	No			No
<a href="#">Biotechnologie Avanzate SCARL</a>	CEINGE	Research Associations/ Foundations	Research, Engineering & Biotechnology, Health care	National	Italy	Medium	No			No
<a href="#">CARDIOVASCULARREsolution of INflammation to promote HEALTH</a>	CARE-IN-HEALTH	(EU) Projects	Research, CI, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	Yes	Developer	Communicate	No
<a href="#">CARTHAGO ITN</a>		(EU) Projects	Research, Health care, CI, RD,	European		Medium	No			No

			Engineering & Biotechnology							
<a href="#">Celiac Disease Genomic Environmental Microbiome and Metabolomic</a>	CDGEMM	(EU) Projects	Research, Health care, AI, Digital Health Solutions, Microbiome	European		Medium	No			Yes
<a href="#">Cell and tissue engineering laboratory of the Galeazzi Institute in Milan</a>		R&D institutions/ centers	Research, Engineering & Biotechnology	National	Italy	Medium	No			Yes
<a href="#">Centre for research &amp; Technology Hellas, Information Technologies Institute, Greece</a>		R&D institutions/ centers	Research, Engineering & Biotechnology, AI, Digital health solutions	National	Greece	Medium	No			No
<a href="#">CNTESIS, Portugal</a>		R&D institutions/ centers	Research	National	Portugal	Medium	No			Yes
<a href="#">COST Action "Building an open European Network on OsteoArthritis research"</a>	NetwoArk	(EU) Projects	Research, Health care, CI, RD, Engineering & Biotechnology	European		High	Yes	Enabler, Developer	Communicate, collaborate	Yes
<a href="#">COST action "Tendon Regeneration Network"</a>	TENET	(EU) Projects	Research, Health care, CI, RD, Engineering & Biotechnology	European		Medium	No			Yes
<a href="#">Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands</a>		Academic institution	Research, Gastroenterology, Microbiome, Clinical trials	National	Netherlands	Medium	No			Yes
<a href="#">Development of a World-Level Neuroengineering Research Centre by European Twinning</a>	BrainTwin	(EU) Projects	Research, Health care	European		Medium	No			Yes

<a href="#">Digital Health &amp; Technology EULAR Study Group</a>		Research Associations/ Foundations	Research, AI, Digital health solutions	European		High	No			No
<a href="#">Digital Health Uptake</a>	DHU	(EU) Projects	Research, Health care, Digital health solutions, policy	European		Medium	No			Yes
<a href="#">Discovering chronic inflammation biomarkers that define key stages in the Healthy-to-NASH (non-alcoholic steatohepatitis) transition to inform early prevention and treatment strategies</a>	halt-ROININ	(EU) Projects	Research, CI, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			Yes
<a href="#">Early Interception of Inflammatory-mediated Type 2 Diabetes</a>	INTERCEPT-2D	(EU) Projects	Research, CI, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			No
<a href="#">Emerging EULAR Network</a>	EMEUNET	Research Associations/ Foundations	Other	European		Medium	Yes	Developer	Collaborate	Yes
<a href="#">ENRICH Global</a>		(EU) Projects	Research, Health care, Policy	European		Medium	No			No
<a href="#">Enterprise Europe Network</a>	EEN	Research Associations/ Foundations	Other	European		Medium	No			No
<a href="#">EULAR Big Data in RMDs Study Group</a>		Research Associations/ Foundations	Research, CI, RD, Health care, Policy, Cohort/ study	European		High	No			No
<a href="#">EULAR Epidemiology and Registeries Study Group</a>		Research Associations/ Foundations	Research, CI, RD, Health care, Policy,	European		High	No			No

			Cohort/ study, Clinical trials							
<a href="#">EULAR European Consensus Finding Study Group on Laboratory Investigation in Rheumatology</a>	ECFSG	Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">EULAR Gene and Cell Therapy Study Group</a>	GCTSG	Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">EULAR Public Health in RMDs Study Group</a>		Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">EULAR Study Group for Risk Factors for RA</a>	SGFRA	Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">EULAR Study Group on Capillaroscopy &amp; Micro-circulation in Rheumatic Diseases</a>		Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">EULAR study group on MHC-I-opathy</a>		Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">EULAR Study Group on Neuro Endocrine Immunology of the Rheumatic Diseases</a>	NEIRD	Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">EULAR Study Group on OA</a>	SGOA	Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">EULAR Study Group on Social Media for Rheumatology Healthcare Professionals</a>	SoMeR	Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	Yes	Enabler	Advocate, consult, collaborate	No

<a href="#">EULAR Study Group RMD Skeletal Muscle Research</a>		Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">EULAR Study Group Syndemics in Rheumatic and Musculoskeletal Disease</a>		Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">EULAR Synovitis Study Group</a>	ESSG	Research Associations/ Foundations	Research, CI, RD, Health care, Policy	European		High	No			No
<a href="#">European Partnership for Personalised Medicine</a>	EP PerMed	(EU) Projects	Research, Health care, policy	European		High	No			Yes
<a href="#">Experimental and Observational Rheumatology, Health Research Institute of Santiago de Compostela (IDIS)</a>		R&D institutions/ centers	Research, CI, RD, Health care	National	Spain	Medium	No			Yes
<a href="#">French National Institute of Health and Medical Research</a>	INSERM	R&D institutions/ centers	Research, CI, RD, Nutrition, Microbiome	National	Spain	Medium	No			No
<a href="#">Friederich Alexander Universität Erlangen Nürnberg</a>	FAU	Academic institution	Research	National	Germany	Medium	Yes	Developer	Collaborate	Yes
<a href="#">Fundació Centre Tecnològic de Catalunya</a>	Eurecat	Research Associations/ Foundations	Research, Engineering & Biotechnology	Regional	Spain, Catalunya	Low	No			No
<a href="#">Fundación Biomédica Galicia Sur</a>		Research Associations/ Foundations	Research, Engineering & Biotechnology	Regional	Spain, Galicia	Low	No			Yes
<a href="#">Fundación Institut d'Investigació Biomèdica de Girona</a>	IDIBGI	Research Associations/ Foundations	Research, Engineering & Biotechnology	National	Spain	Medium	No			No

<a href="#">Fundación Instituto de Investigación Biomédica de A Coruña</a>	INIBIC	Research Associations/ Foundations	Research, Engineering & Biotechnology	Regional	Spain, Coruña	low	No			Yes
<a href="#">Fundación Universitaria Sanitas</a>		Research Associations/ Foundations	Research, Engineering & Biotechnology, Health care, Digital health solutions	National	Colombia	Medium	No			No
<a href="#">Gastroenterology, Leiden University Medical Centre</a>	LUMC	Academic institution	Research, Gastroenterology, Microbiome, Clinical trials	National	Netherlands	Medium	No			Yes
<a href="#">Genome, Environment, Microbiome and Metabolome in Autism</a>	GEMMA	(EU) Projects	Research, Health care, AI, Digital Health Solutions	European		Medium	No			Yes
<a href="#">German Alliance for Global Health Research</a>	GLOHRA	Research Associations/ Foundations	Research, Health care, policy	National	German	Medium	No			No
<a href="#">Glycans as master triggers of health to intestinal inflammation transition</a>	Gly-canTrigger	(EU) Projects	Research, CI, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	Yes	Developer	Collaborate	Yes
<a href="#">Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response</a>	ONCOBI-OME	(EU) Projects	Research, CI, Microbiome, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			No
<a href="#">Health initiatives in psoriasis and psoriatic arthritis consortium European states</a>	HIPPOCRATES	(EU) Projects	Research, CI, Health care, RD, AI, Digital health solutions	European		Medium	No			Yes

<a href="#">Health-NCP-Net</a>	HNN3.0	(EU) Projects	Research, Health care, policy	European		Medium	No			No
<a href="#">Humanitas University in Milan</a>		Academic institution	Research	National	Italy	Medium	Yes	Developer	Collaborate	Yes
<a href="#">Imminent Disease Prediction and Prevention at the Environment Host Interface</a>	IMMEDIATE	(EU) Projects	Research, CI, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			Yes
<a href="#">Imperial College of Science, Technology and Medicine</a>		Academic institution	Research	National	UK	Medium	No			No
<a href="#">INESCTEC, Portugal</a>		R&D institutions/ centers	Research	National	Portugal	Medium	No			Yes
<a href="#">Inflammation in human early life: targeting impacts on life-course health</a>	INITALISE	(EU) Projects	Research, CI, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			Yes
<a href="#">Institut national de la recherche agronomique</a>	INRA	Research Associations/ Foundations	Research, Health care, policy	National	France	Medium	No			No
<a href="#">Institut national de la santé et de la recherche médicale</a>	INSERM	Research Associations/ Foundations	Research, Health care, policy	National	France	Medium	No			No
<a href="#">Institute for Food &amp; Health, Germany</a>	ZIEL	R&D institutions/ centers	Research	National	France	Medium	Yes	End user	Communicate, collaborate	No
<a href="#">Institute of Environmental Health, Faculty of Medicine, University of Lisbon</a>	ISAMB	Academic institution	Research, CI, Health care	National	Portugal	Medium	No			Yes

<a href="#">Instituto de saúde pública da universidade do Porto</a>	ISPUP	Research Associations/ Foundations	Research, Health Care, Policy	National	Portugal	Medium	No			Yes
<a href="#">International Cartilage Regeneration &amp; Joint Preservation Society</a>	ICRS	Research Associations/ Foundations	Research, RD, CI, policy	International		High	Yes	Enabler	Communicate	Yes
<a href="#">International Consortium for Personalised Medicine</a>	ICPerMed	(EU) Projects	Research, Health care, policy	European		High	No			Yes
<a href="#">International Genetics of Ankylosing Spondylitis</a>	IGAS	Research Associations/ Foundations	Research, CI, RD, Health care	International		Medium-High	No			Yes
<a href="#">International Iberian Nanotechnology Laboratory</a>	INL	R&D institutions/ centers	Research, Engineering & Biotechnology	International		Medium	No			Yes
<a href="#">International Society for Computational Biology</a>	ISCB	Research Associations/ Foundations	Research, AI, Digital health solutions, policy	International		High	No			No
<a href="#">Istanbul Medipol University</a>		Academic institution	Research	National	Turkey	Medium	No			No
<a href="#">Italian Research Group in Clinical Rheumatology</a>	GIRRCS	Research Associations/ Foundations	Research, CI, RD, Health care, clinical trial	National	Italy	Medium	Yes	Developer, Enabler	Communicate, collaborate	Yes
<a href="#">Joanneum Research</a>		Research Associations/ Foundations	Research, Engineering & Biotechnology	National	Austria	Medium	Yes	Developer	Communicate	No
<a href="#">John Hopkins University</a>		Academic institution	Research	National	USA	Medium	No			No
<a href="#">Kennedy Institute of Rheumatology, UK</a>		R&D institutions/ centers	Research	National	UK	Medium	No			Yes
<a href="#">LongCOVID - decision support for prediction and management of LCS</a>	LongCOVID	(EU) Projects	Research, Health care, Biomarkers, Cohorts/ study,	European		Medium	No			Yes

			Digital health solutions, Clinical trials							
<a href="#">Maugeri Clinical Scientific Institutes</a>		R&D institutions/ centers	Research, Health care	National	Italy	Medium	Yes	Developer	Collaborate	Yes
<a href="#">Mayo clinic</a>		R&D institutions/ centers	Research, CI, RD, Clinical trials	National	Spain	Medium	No			Yes
<a href="#">Microbiology and Biotechnology Doctoral program University of Helsinki</a>	MBDP	Academic institution	Research, Microbiome, Engineering & Biotechnology	National	Finland	Medium	No			Yes
<a href="#">MICROBiome-based biomarkers to PREDICT decompensation of liver cirrhosis and treatment response</a>	MICROB-PREDICT	(EU) Projects	Research, CI, Microbiome, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			No
<a href="#">Microbiota and Mucosal Barrier Research in Rheumatic and Musculoskeletal Diseases EULAR study group</a>	EULAR MICMUC group	Research Associations/ Foundations	Research, RD, CI, policy	European		High	Yes	Enabler, Developer	Advocate, consult, collaborate	Yes
<a href="#">Molecular and Cellular Gastroenterology, Health Research Institute of Santiago de Compostela (IDIS)</a>		R&D institutions/ centers	Research, Gastroenterology, Microbiome	National	Spain	Medium	No			Yes
<a href="#">Mucus-Penetrating Microbiota: Characterization, Mechanism and Therapeutic in Metabolic Disease</a>	INVADERS	(EU) Projects	Research, CI, RD, Health care, AI, Digital health solutions, clinical trials, microbiota, biomarkers, biomarkers	European		Medium	No			No
<a href="#">Netherlands Donor Feces Bank (NDFB)</a>	NDFB	Cohort/ Biobank	Research, CI, Health care, Cohort/ study,	National	Netherlands	Medium	No			Yes

			Clinical study, Microbiome							
<a href="#">Neuroendocrine Interactions in Rheumatic and Inflammatory Diseases, Health Research Institute of Santiago de Compostela (IDIS)</a>		R&D institutions/ centers	Research, CI, RD, Health care	National	Spain	Medium	No			Yes
<a href="#">Nutricia Research</a>		Research Associations/ Foundations	Research, Engineering & Biotechnology, Microbiome, Health Care, Nutrition	International		Medium	No			No
<a href="#">Nutrition Laboratory, Faculty of Medicine, University of Lisbon</a>		Academic institution	Research, CI, RD, Nutrition, Microbiome	National	Portugal	Medium	No			Yes
<a href="#">Optimise and predict antidepressant efficacy</a>	OPADE	(EU) Projects	Research, Health care, AI, Digital Health Solutions	European		Medium	No			Yes
<a href="#">Osteoarthritis Research Society International</a>	OARSI	Research Associations/ Foundations	Research, RD, CI, policy	International		High	Yes	Enabler	Communicate, advocate, co-create	Yes
<a href="#">Outcomes Research in Rheumatology</a>	OMERACT	Research Associations/ Foundations	Research, RD, policy	International		High	No			Yes
<a href="#">P4FIT</a>		(EU) Projects	Research, Health care, CI, RD, Engineering & Biotechnology	European		Medium	No			No
<a href="#">Paris-Saclay University - 2i infection &amp; inflammation</a>	UVSQ	Academic institution	Research, CI	National	France	Medium	No			Yes

<a href="#">Personalised blueprint in-testinal health</a>	miGut-Health	(EU) Projects	Research, CI, Health care, AI, Digital health solutions, clinical trials, biomarkers, microbiome	European		Medium	No			Yes
<a href="#">Personalised organ-on-chips for drug screening in rheumatoid arthritis</a>	FLAMIN-GO	(EU) Projects	Research, CI, Organ-on-a-chip, Health care, AI, Digital health solutions, clinical trials, RD, biomarkers	European		Medium	No			No
<a href="#">PeRsOnalised Prevention roadmap for the future HEalThcare in Europe</a>	PROPHET	(EU) Projects	Research, Health care, policy	European		High	No			No
<a href="#">Physic informed machine learning-based prediction and reversion of impaired fasting glucose management</a>	PRAESII-DIUM	(EU) Projects	Research, CI, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			No
<a href="#">PMF Research, Italy</a>		R&D institutions/centers	Research, AI, Digital health solutions	National	Italy	Medium	No			No
<a href="#">Polytechnic University of Cartagena, Spain</a>		Academic institution	Research	National	Spain	Medium	No			No
<a href="#">Precision medicine for musculoskeletal regeneration, prosthetics and active ageing</a>	PREMUR-ROSA	(EU) Projects	Research, CI, RD, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			Yes
<a href="#">Psoriatic arthritis inflammation explained through multi-source data analysis guiding a novel</a>	iPROLEPSIS	(EU) Projects	Research, CI, RD, Health care, AI, Digital health	European		Medium	No			Yes

<a href="#">personalised digital care ecosystem</a>			solutions, clinical trials, biomarkers							
<a href="#">Queensland University - Frazer Institute</a>		Academic institution	Research	National	Australia	Medium	Yes	Developer	Collaborate	Yes
<a href="#">Regenerative medicine &amp; stem cells, University Medical Center in Utrecht</a>	UMC	Academic institution	Research, Clinical trials	National	Netherlands	Medium	No			Yes
<a href="#">Rheumatoid Arthritis Caught Early: investigating biological mechanisms preceding chronic inflammation to identify patients prior to presentation of classic chronic arthritis</a>	RACE	(EU) Projects	Research, CI, RD, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			No
<a href="#">Rheumatology, Health Research Institute of Santiago de Compostela (IDIS)</a>		R&D institutions/ centers	Research, CI, RD	National	Spain	Medium	No			Yes
<a href="#">Screen-RA</a>		Cohort/ Biobank	Research, CI, Health care, RD, Cohort/ study, Clinical study	National	Switzerland	Medium	No			No
<a href="#">Smart and Healthy Ageing through People Engaging in Supportive Systems</a>	SHAPES	(EU) Projects	Research, Health care, AI, Digital Health Solutions	European		Medium	No			No
<a href="#">Smart Health Innovation &amp; Future Technologies Hub</a>	SHIFT-Hub	(EU) Projects	Research, Health care, Digital health solutions	European		Medium	No			Yes
<a href="#">SPIDeRR</a>	SPIDeRR	(EU) Projects	Research, CI, RD, Health care, AI, Digital health	European		Medium	No			Yes

			solutions, clinical trials, biomarkers							
<a href="#">SQUEEZE</a>	SQUEEZE	(EU) Projects	Research, CI, RD, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			Yes
<a href="#">Stichting Universitaire en Algemene Kinder- en Jeugdpsychiatrie Noord-Nederland in Assen</a>		Academic institution	Research	National	Netherlands	Medium	No			No
<a href="#">Stratification of obese phenotypes to optimize future obesity therapy</a>	SOPHIA	(EU) Projects	Research, Health care, Cohort/ study, Clinical study, AI, Digital Health Solutions	European		Medium	No			Yes
<a href="#">Stratification of Rheumatoid Arthritis: Computational models to personalize management strategies for difficult-to-treat disease</a>	STRATA-FIT	(EU) Projects	Research, CI, RD, Health care, AI, Digital health solutions, clinical trials, biomarkers	European		Medium	No			Yes
<a href="#">Tampere University</a>		Academic institution	Research	National	Finland	Medium	No			No
<a href="#">Technical University of Denmark</a>	DTU	Academic institution	Research	National	Denmark	Medium	No			Yes
<a href="#">The European Fecal Microbiota Transplantation Network of academics</a>	EurFMT	Research Associations/ Foundations	Microbiome, Policy	European		High	Yes	Enabler, Observer	Co-create, advocate	Yes
<a href="#">The European Partnership on transforming health and care systems</a>	THCS	(EU) Projects	Research, Health care, Digital health solutions, policy	European		Medium	No			No

<a href="#">The Genetics of Osteoarthritis</a>	GO	Research Associations/ Foundations	Research, CI, RD	International		High	Yes	Enabler, End user	Communicate, collaborate	Yes
<a href="#">The National Research Council Italy</a>	CNR	Research Associations/ Foundations	Research, Health care, policy	National	Italy	Medium	No			No
<a href="#">tissue regeneration and aging, Ludwig Boltzmann Institute for Traumatology, Austria</a>		R&D institutions/ centers	Research, CI, RD, Nutrition, Microbiome	National	Austria	Medium	No			Yes
<a href="#">translational immunology program at UH</a>	TRIMM	(EU) Projects	Research, Health care	Regional	Helsinki	Low	No			Yes
<a href="#">UCB - Biopharma SRL</a>		R&D institutions/ centers	Research, Engineering & Biotechnology	International		Medium	No			Yes
<a href="#">Universidade da Coruña</a>	UDC	Academic institution	Research	National	Spain	Medium	No			Yes
<a href="#">Universidade de Santiago de Compostela</a>	USC	Academic institution	Research	National	Spain	Medium	No			Yes
<a href="#">Università Cattolica del Sacro Cuore, Gastroenterology and Digestive Endoscopy, Italy</a>		Academic institution	Research, CI, Gastroenterology, Microbiome	National	Italy	Medium	No			Yes
<a href="#">Università Cattolica del Sacro Cuore, Rheumatology Unit</a>	UNICATT	Academic institution	Research, CI, RD, Microbiome	National	Italy	Medium	No			Yes
<a href="#">Università degli Studi di Napoli 'Federico II', Department of Pharmacology</a>		Academic institution	Research	National	Italy	Medium	No			Yes
<a href="#">Università degli Studi di Siena</a>		Academic institution	Research	National	Italy	Medium	No			No

<a href="#">University of Bergen, Department of Clinical Medicine, Norway</a>		Academic institution	Research, CI, RD, Health care	National	Norway	Medium	No			No
<a href="#">University of Calgary</a>		Academic institution	Research, CI, RD, Health care	National	Canada	Medium	Yes	Developer	Collaborate	Yes
<a href="#">University of Copenhagen, Microbiome Systems Biology</a>		Academic institution	Research, CI, microbiome	National	Denmark	Medium	Yes	Developer	Communicate	No
<a href="#">University of Galway</a>		Academic institution	Research	National	Ireland	Medium	No			No
<a href="#">University of Harvard, Faculty of Medicine, Department of Pediatrics</a>		Academic institution	Research, Health care, Clinical trials	National	USA	Medium	No			No
<a href="#">University of Helsinki, Doctoral Programme in Biomedicine</a>	DPBM	Academic institution	Research	National	Finland	Medium	No			Yes
<a href="#">University of Helsinki, Doctoral Programme in Drug Research</a>	DPDR	Academic institution	Research	National	Finland	Medium	No			Yes
<a href="#">University of Helsinki, Institute for Molecular Medicine, FIMM Genomics</a>	FIMM GENOMICS	Academic institution	Research	National	Finland	Medium	No			Yes
<a href="#">University of Naples Federico II, Department of Chemical Sciences</a>	UNINA	Academic institution	Research	National	Finland	Medium	Yes	Developer	Collaborate	Yes
<a href="#">University of Southern Denmark - Research unit of Rheumatology</a>	SDU	Academic institution	Research, CI, RD, Microbiome	National	Denmark	Medium	No			Yes
<a href="#">University of Toronto - Institute of Medical Science</a>	IMS - UoT	Academic institution	Research	National	Canada	Medium	Yes	Developer	Collaborate	Yes
<a href="#">University of Zürich, Switzerland</a>	UZH	Academic institution	Research, CI, RD, Health care	National	Switzerland	Medium	No			Yes

<a href="#">University of Helsinki, Antigen-specific Immune Tolerance Induction in Autoimmune Diseases reserach group</a>		Academic institution	Research, CI	National	Finland	Medium	No			Yes
<a href="#">Univesity of Helsinki, clonal hematopoiesis re-search group</a>		Academic institution	Research	National	Finland	Medium	No			Yes
<a href="#">Univesity of Helsinki, Extra-cellular vesicles core</a>	EV CORE	Academic institution	Research	National	Finland	Medium	No			Yes
<a href="#">Univesity of Helsinki, Faculty of Medicine, Department of Bacteriology and Immunology</a>		Academic institution	Research, CI, RD, Microbiome	National	Finland	Medium	No			Yes
<a href="#">Univesity of Helsinki, Faculty of Medicine, Department of Oncology</a>		Academic institution	Research, Clinical trials	National	Finland	Medium	No			Yes
<a href="#">Univesity of Helsinki, Faculty of Pharmacy, Division of Pharmaceutical Biosciences</a>		Academic institution	Research	National	Finland	Medium	No			Yes
<a href="#">Univesity of Helsinki, Functional Genomics Unit</a>	FUGU	Academic institution	Research	National	Finland	Medium	Yes	Developer	Collaborate, use of service	Yes
<a href="#">Univesity of Helsinki, immuno-oncology lab</a>		Academic institution	Research	National	Finland	Medium	No			Yes
<a href="#">Univesity of Helsinki, Institute of Biotechnology, DNA sequencing and genomics</a>	BIDGEN	Academic institution	Research	National	Finland	Medium	Yes	Developer	Collaborate, use of service	Yes
<a href="#">Univesity of Helsinki, Neuroimmunology and de-generation reserach group</a>		Academic institution	Research, CI	National	Finland	Medium	No			No

<a href="#">Univesity of Helsinki,Im-mune cell signaling re-search group</a>		Academic insti-tution	Research	National	Finland	Medium	No			Yes
<a href="#">Univesity of Helsinki,Im-munomics research group</a>		Academic insti-tution	Research	National	Finland	Medium	No			Yes
<a href="#">Utrecht University</a>		Academic insti-tution	Research	National	Nether-lands	Medium	No			No
<a href="#">Utrecht University Medical Center, Netherlands</a>		Academic insti-tution	Research, CI, RD, Animal models	National	Nether-lands	Medium	Yes	Developer	Collaborate	Yes
<a href="#">VIB Center for Inflamma-tion Research, Belgium</a>		R&D institutions/ centers	Research	National	Bel-gium	Medium	No			Yes
<a href="#">VLAG Graduate School, Netherlands</a>		Academic insti-tution	Research	National	Nether-lands	Medium	No			Yes
<a href="#">Wagening University, Netherlands</a>		Academic insti-tution	Research, CI, RD, Microbiome	National	Nether-lands	Medium	No			Yes
<a href="#">Weizmann Institute of Sci-ence, Department of Mo-lecular Cell Biology, Israel</a>		R&D institutions/ centers	Research	National	Israel	Medium	No			No
<b>End Users</b>										
<a href="#">Academia Europea de Pacientes sobre Innova-ción Terapéutica</a>	EUPATI Spain	Network/ Patient Associations	Health care, Rese-arch, Policy	European		Medium				Yes
<a href="#">AGE Platform</a>	AGE	Network/ Patient Associations	Health care, Rese-arch, Policy	European		Medium	No			No
<a href="#">Arthritis Life</a>		Citizens	CI, RD	International		Medium	No			No
<a href="#">Asociación Española con la Osteoporosis y la Artro-sis</a>	AECOSAR	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Spain	Medium	No			No

<a href="#">Assessment of Spondylo Arthritis international Society</a>	ASAS	Network/ Patient Associations	CI, RD, Health care, Research, Policy	International		Medium	Yes	End User, Enabler	Communicate, consult, collaborate	Yes
<a href="#">Associação Nacional de Doentes com Artrites e Reumatismos da Infância</a>	ANDAI	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Portugal	Medium	Yes	End User	Communicate, collaborate, consult	Yes
<a href="#">Associazione Nazionale Malati Reumatici</a>	ANMAR	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Italy	Medium	No			Yes
<a href="#">Austrian Society for Geriatrics and Gerontology</a>	ÖGGG	Other Healthcare Workers	Policy, Health care, RD	National	Austria	Medium	Yes	End User	Communicate, Consult	No
<a href="#">Austrian Society for Orthopaedics and Orthopaedic Surgery</a>	ÖGO	Other Healthcare Workers	Policy, Health care, RD	National	Austria	Medium	Yes	End User	Communicate, Consult	No
<a href="#">British Society of Rheumatology</a>	BSR	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	UK	Medium	No			No
<a href="#">Centro Hospitalar Universitário Lisboa Norte, Paediatric Rheumatology Unit</a>		Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	Lisbon, Portugal	Low-Medium	No			Yes
<a href="#">Cheryl Crow (Patient advocate)</a>		Citizens	CI, RD	International		Medium	No			No
<a href="#">Coalition of Patients' organisations with chronic diseases romania</a>	COPAC	Network/ Patient Associations	Health care, Research, Policy, CI	National	Romania	Medium	No			No
<a href="#">Complejo Hospitalario Universitario de A Coruña</a>	CHUAC	Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	Spain, Coruña	Low-Medium	No			Yes
<a href="#">Complejo Hospitalario Universitario de Santiago de Compostela</a>	CHUS	Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	USA, Massachusetts	Low-Medium	No			Yes

<a href="#">Complejo Hospitalario Universitario de Vigo</a>	CHUVI	Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	Spain, Vigo	Low-Medium	No			Yes
<a href="#">Coordinadora Española de Asociaciones de Espondiloartritis</a>	CEADE	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Spain	Medium	No			No
<a href="#">Czech Society of Rheumatology</a>	CSR	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Czechia	Medium	No			No
<a href="#">Deutsche Gesellschaft für Rheumatologie e.V.</a>	DGRh	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Germany	Medium	No			No
<a href="#">Dutch Reumapatiëntenbond</a>	Reumapatiëntenbond (BOND)	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Netherlands	Medium	No			No
<a href="#">e-seniors</a>		Network/ Patient Associations	Health care, Research, Digital health solutions	European		Medium	No			No
<a href="#">Estonian Association of Gerontology and Geriatrics</a>	EGGA	Other Healthcare Workers	Policy, Health care, RD	National	Estonia	Medium	No			No
<a href="#">Estonian Orthopaedic Society</a>	EOS	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Estonia	Medium	No			No
<a href="#">Estonian Orthopaedic Society</a>		Other Healthcare Workers	Policy, Health care, RD	National	Estonia	Medium	No			No
<a href="#">Estonian Society for Rheumatology</a>	ESR	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Estonia	Medium	No			No
<a href="#">EULAR People with Arthritis / Rheumatism across Europe</a>	EULAR PARE	Network/ Patient Associations	CI, RD, Health care, Research, Policy	European		High	Yes	End User	Communicate, consult, collaborate	Yes
<a href="#">EULAR Young PARE Podcast</a>		Citizens	CI, RD	European		Medium	No			No

<a href="#">European Alliance of Associations for Rheumatology</a>	EULAR	Network/ Patient Associations	CI, RD, Health care, Research, Policy	European		High	Yes	End User, Enabler	Communicate, consult, collaborate	Yes
<a href="#">European Network for Children with Arthritis</a>	ENCA	Network/ Patient Associations	CI, RD, Health care, Research, Policy	European		Medium	Yes	End User	Communicate, collaborate, consult	Yes
<a href="#">European Patient Forum</a>	EPF	Network/ Patient Associations	Health care, Research, Policy	European		Medium	No			No
<a href="#">European Personalized Medicine Association</a>	EPEMED	Network/ Patient Associations	Health care, Research, Policy	European		Medium	Yes	End User	Communicate, collaborate, consult	No
<a href="#">Finnish Association of Physiotherapists</a>		Other Healthcare Workers	Policy, Health care, RD	National	Finland	Medium	No			No
<a href="#">Finnish Geriatrics Association</a>		Other Healthcare Workers	Policy, Health care, RD	National	Finland	Medium	No			Yes
<a href="#">Finnish Orthopaedic Association</a>		Other Healthcare Workers	Policy, Health care, RD	National	Finland	Medium	Yes	End User	Communicate, consult	Yes
<a href="#">Finnish Rheumatism Association</a>	Reumaliitto	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Finland	Medium	Yes	End User	Communicate, consult	Yes
<a href="#">German Association for Physiotherapy</a>		Other Healthcare Workers	Policy, Health care, RD	National	Germany	Medium	No			No
<a href="#">German Society for Orthopaedics and Trauma Surgery</a>	DGOU	Other Healthcare Workers	Policy, Health care, RD	National	Germany	Medium	No			No
<a href="#">Helsinki University Hospital</a>	HUS	Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	Finland, Helsinki	Low-Medium	Yes	End User	Communicate, consult, collaborate	Yes
<a href="#">Hey OA! Podcast</a>	Hey OA!	Citizens	CI, RD	International		Medium	Yes	Enabler	Communicate	Yes
<a href="#">HMC Hospital Leiden</a>		Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	Netherlands, Leiden	Low-Medium	No			Yes

<a href="#">Italian Physiotherapists Association</a>	AIFI	Other Healthcare Workers	Policy, Health care, RD	Natinonal	Italy	Medium	No			No
<a href="#">Italian Society of Gerontology and Geriatrics</a>	SIGG	Other Healthcare Workers	Policy, Health care, RD	Natinonal	Italy	Medium	No			No
<a href="#">Italian Society of Rheumatology</a>	SIR	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Italy	Medium-High	Yes	End User, Enabler	Communicate, advocate, consult, collaborate	Yes
<a href="#">Joel Nelson (Patient advocat)</a>		Citizens	CI, RD	International		Medium	No			No
<a href="#">Kuopio University Hospital</a>	KUH	Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	Finland, Kuopio	Low-Medium	Yes	End User	Communicate, consult, collaborate	Yes
<a href="#">Liga Portuguesa contra as Doenças Reumáticas</a>	LPCDR	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Portugal	Medium	No			Yes
<a href="#">Liga Reumatológica Española</a>	LIRE	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Spain	Medium	Yes	End User	Communicate, collaborate, consult	Yes
<a href="#">Maison Sport Santé in the North of Essonne</a>		Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	France, Essonne	Low-Medium	No			No
<a href="#">Massachusetts General Hospital for Children, Division of Pediatric Gastroenterology and Nutrition</a>		Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	USA, Massachusetts	Low-Medium	No			No
<a href="#">Netherlands Society of Gastroenterology (NVGE)</a>	NVGE	Network/ Patient Associations	Health care, Research, Gastroenterology, Microbiome	National	Netherlands	Medium	No			No
<a href="#">Osteoarthritis Foundation International</a>	OaFi	Network/ Patient Associations	CI, RD, Health care, Research, Policy	International		Medium	Yes	End User	Communicate, collaborate	No

<a href="#">Paediatric Rheumatology European Society</a>	PREs	Network/ Patient Associations	CI, RD, Health care, Research, Policy	European		High	Yes	End User	Communicate, collaborate, consult	Yes
<a href="#">Päijät-Häme Central Hospital, Lahti, Finland</a>		Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	Finland, Lahti	Low-Medium	Yes	End User	Communicate, consult, collaborate	Yes
<a href="#">Patients network for medical research and health</a>	EGAN	Network/ Patient Associations	Health care, Research, Policy, Cohort/ studies, Clinical trials	European		Medium	Yes	End User	Communicate, collaborate, consult	No
<a href="#">Physio Austria</a>		Other Healthcare Workers	Policy, Health care, RD	National	Austria	Medium	Yes	End User	Communicate, Consult	No
<a href="#">Physioswiss - Swiss Physiotherapy Association</a>		Other Healthcare Workers	Policy, Health care, RD	National	Switzerland	Medium	No			No
<a href="#">Portuguese Association of Physiotherapists</a>	APFISIO	Other Healthcare Workers	Policy, Health care, RD	National	Portugal	Medium	No			Yes
<a href="#">Portuguese Society of Geriatrics and Gerontology</a>	PDGG	Other Healthcare Workers	Policy, Health care, RD	National	Portugal	Medium	No			Yes
<a href="#">Portuguese Society of Orthopaedics and Traumatology</a>	SPOT	Other Healthcare Workers	Policy, Health care, RD	National	Portugal	Medium	No			Yes
<a href="#">Rheumaliga Schweiz</a>		Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Switzerland	Medium	No			No
<a href="#">Sociedad Espanola de Reumatologia</a>	SER	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Spain	Medium	No			Yes
<a href="#">Sociedade Portuguesa de Reumatologia</a>		Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Portugal	Medium	Yes	End User	Communicate, collaborate, consult	Yes
<a href="#">Sociedade Portuguesa de Reumatologia Pediátrica</a>		Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Portugal	Medium	No			Yes

<a href="#">Societal Impact of Pain</a>	SIP	Network/ Patient Associations	CI, RD, Health care, Research, Policy	European		Medium	No			No
<a href="#">Spanish General Council of Physiotherapists' Associations</a>		Other Healthcare Workers	Policy, Health care, RD	Natinonal	Spain	Medium	No			No
<a href="#">Spanish Society of Orthopaedic Surgery and Traumatology</a>	SECOT	Other Healthcare Workers	Policy, Health care, RD	Natinonal	Spain	Medium	No			Yes
<a href="#">Swedish Rheumatism Association</a>	Reumatikerförbundet	Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	Sweden	Medium	No			No
<a href="#">Swiss Association for Gerontological Nursing</a>	SAGN	Other Healthcare Workers	Policy, Health care, RD	Natinonal	Switzerland	Medium	No			No
<a href="#">Swiss Orthopaedics</a>		Other Healthcare Workers	Policy, Health care, RD	Natinonal	Switzerland	Medium	No			No
<a href="#">Swiss Society of Geriatrics</a>	SFGG	Other Healthcare Workers	Policy, Health care, RD	Natinonal	Switzerland	Medium	No			No
<a href="#">The Chronic Pain Club</a>		Citizens	CI, RD	International		Medium	No			No
<a href="#">The Estonian Association of Physiotherapists</a>		Other Healthcare Workers	Policy, Health care, RD	Natinonal	Estonia	Medium	No			No
<a href="#">The European Musculoskeletal Conditions Surveillance and Information Network</a>	eumusc	Network/ Patient Associations	CI, RD, Health care, Research, Policy	European		Medium	No			No
<a href="#">The General Hospital Corporation d/b/a Massachusetts General Hospital</a>		Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	USA, Massachusetts	Low-Medium	No			No
<a href="#">The German Society for Geriatrics</a>	DGG	Other Healthcare Workers	Policy, Health care, RD	Natinonal	Germany	Medium	No			No

<a href="#">The Joint Action Podcast</a>	Joint Action	Citizens	CI, RD	International		Medium	No			No
<a href="#">The Spanish Society of Geriatrics and Gerontology</a>	SEGG	Other Healthcare Workers	Policy, Health care, RD	National	Spain	Medium	No			No
<a href="#">University Paediatrics Clinic, Faculty of Medicine, University of Lisbon</a>		Clinicians/ Clinics	CI, RD, Health care, Research, Clinical trials	Regional	Lisbon, Portugal	Low-Medium	No			No
<a href="#">Versus Arthritis</a>		Network/ Patient Associations	CI, RD, Health care, Research, Policy	National	USA	Medium	No			No
<b>(Public) Authorities</b>										
<a href="#">National Institute for Health Research UK</a>	NIHR	Authorities and regulatory bodies	Policy, Health care	National	UK	Medium-high	No			No
<a href="#">Swedish Agency for Health Technology Assessment and Assessment of Social Services</a>	SBU	Authorities and regulatory bodies	Policy, Health care	National	Switzerland	Medium-high	No			No
<a href="#">Swiss Federal Office of Public Health</a>	SFOPH	Authorities and regulatory bodies	Policy, Health care	National	Switzerland	Medium-high	No			Yes
<a href="#">Agència de Qualitat i Avaluació Sanitàries de Catalunya</a>	AQuAS	Authorities and regulatory bodies	Policy, Health care	Regional	Spain, Catalunya	Low-Medium	No			No
<a href="#">Agency for Health Technology Assessment and Tariff System Poland</a>	AOTMiT	Authorities and regulatory bodies	Policy, Health care	National	Poland	Medium-high	No			No
<a href="#">All digital</a>		Educational Authority	Policy, Health care	European		Medium-high	No			No

<a href="#">Assistance publique- Hôpitaux de Paris</a>	AP-HP	Authorities and regulatory bodies	Policy, Health care	Regional	France, Paris	Low-Medium	No			No
<a href="#">Austrian Agency for Education and Internationalisation</a>	OeAD	Educational Authority	Policy, Health care	National	Austria	Medium-high	yes	Observer, Enabler	Advocate	No
<a href="#">Austrian Federal Office for Safety un Health Care</a>	BASG	Authorities and regulatory bodies	Policy, Health care	National	Austria	Medium-high	No	Observer, Enabler	Advocate	No
<a href="#">Austrian Health Insurance Fund</a>	ÖGK	Health Services & Funds	Policy, Health care	National		Medium-high	yes	Observer, Enabler	Advocate	No
<a href="#">Austrian Institute for Health Technology Assessment</a>	AIHTA	Authorities and regulatory bodies	Policy, Health care	National	Austria	Medium-high	No			No
<a href="#">Austrian Research Promotion Agency</a>	FFG	Funding Agencies & Entities Supporting Research	Policy, Health care	National	Austria	Medium-high	No			No
<a href="#">Austrian Science Fund</a>	FWF	Funding Agencies & Entities Supporting Research	Policy, Health care	National	Austria	Medium-high	No			No
<a href="#">Basque Office for Health Technology Assessment</a>	OSTEBA	Authorities and regulatory bodies	Policy, Health care	Regional	Spain, Basque Country	Low-Medium	No			No
<a href="#">Belgian Health Care Knowledge Centre</a>	KCE	Authorities and regulatory bodies	Policy, Health care	National	Belgium	Medium-high	No			No
<a href="#">Bunsiness Finland</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Finland	Medium-high	No			Yes

<a href="#">Cancer Foundation Finland</a>		Professional Associations	Policy, Health care	National	Finland	Medium-high	No			Yes
<a href="#">Consellería de Educación - Xunta de Galicia</a>		Authorities and regulatory bodies	Policy, Health care	Regional	Spain, Galicia	Low-Medium	No			Yes
<a href="#">Consellería de Saúde - Xunta de Galicia</a>		Authorities and regulatory bodies	Policy, Health care	Regional	Spain, Galicia	Low-Medium	No			Yes
<a href="#">Department of HTA at the State Expert Centre of the Ministry of Health Ukraine</a>	SEC	Authorities and regulatory bodies	Policy, Health care	National	Ukraine	Medium-high	No			No
<a href="#">eMed Germany</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">Estonian Health Insurance Fund</a>		Health Services & Funds	Policy, Health care	National	Estonia	Medium-high	No			No
<a href="#">Estonian Medical Association</a>	EMA	Professional Associations	Policy, Health care	National	Estonia	Medium-high	No			No
<a href="#">Estonian Research Council</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Estonia	Medium-high	No			No
<a href="#">EU Research and innovation funding programme</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	European		Medium-high	No			Yes
<a href="#">European Commission</a>	EC	Authorities and regulatory bodies	Policy, Health care	European		High	yes	Observer, Enabler	Advocate	No

<a href="#">European Health and Digital Executive Agency</a>	HaDEA	Authorities and regulatory bodies	Policy, Health care	European		Medium-high	No			No
<a href="#">European Medicine Agency</a>	EMA	Authorities and regulatory bodies	Policy, Health care	European		Medium-high	Yes	Observer, Enabler	Advocate	Yes
<a href="#">European Regional Development Fund</a>	FEDER	Funding Agencies & Entities Supporting Research	Policy, Health care	European		High	No			No
<a href="#">Federal Institute for Drugs and Medical Devices Germany</a>	BfArM	Authorities and regulatory bodies	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">Federal Ministry of Education and Research Germany</a>	BMBF	Educational Authority	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">Federal ministry of education and research Germany</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">Federal ministry of health Germany</a>	BMG	Authorities and regulatory bodies	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">Federal Ministry Republic of Austria Social Affairs, Health, Care and Consumer Protection</a>		Authorities and regulatory bodies	Policy, Health care	National	Austria	Medium-high	No			No
<a href="#">Federal Office for Public Health Switzerland</a>	FOPH	Authorities and regulatory bodies	Policy, Health care	National	Switzerland	Medium-high	No			No
<a href="#">Federal Social Security Office Germany</a>	BAS	Authorities and regulatory bodies	Policy, Health care	National	Germany	Medium-high	No			No

<a href="#">Finnish Coordinating Center for Health Technology Assessment</a>	FinCCHTA	Authorities and regulatory bodies	Policy, Health care	National	Finland	Medium-high	No			No
<a href="#">Finnish Medical Association</a>		Professional Associations	Policy, Health care	National	Finland	Medium-high	No			Yes
<a href="#">Finska Läka-resällskapet Finland</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Finland	Medium-high	No			No
<a href="#">Foundation for Science and Technology Portugal</a>	FCT	Funding Agencies & Entities Supporting Research	Policy, Health care	National	Portugal	Medium-high	No			Yes
<a href="#">Galician Agency for Health Technology Assessment</a>	AVALIA-T	Authorities and regulatory bodies	Policy, Health care	Regional	Spain, Galicia	Low-Medium	No			Yes
<a href="#">Galician Healthcare service</a>	SERGAS	Authorities and regulatory bodies	Policy, Health care	Regional	Spain, Galicia	Low-Medium	No			Yes
<a href="#">General local health insurance fund Germany</a>	AOK	Health Services & Funds	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">German Medical Association</a>	BAEK	Professional Associations	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">German Research Foundation</a>	DFG	Funding Agencies & Entities Supporting Research	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">Gesundheit Österreich GmbH</a>	GOeG	Authorities and regulatory bodies	Policy, Health care	National	Austria	Medium-high	No			No

<a href="#">Haute Autorité de Santé France</a>	HAS	Authorities and regulatory bodies	Policy, Health care	National	France	Medium-high	No			No
<a href="#">Health Information and Quality Authority Ireland</a>	HIQA	Authorities and regulatory bodies	Policy, Health care	National	Ireland	Medium-high	No			No
<a href="#">Health Technology Assessment international</a>	HTAi	Authorities and regulatory bodies	Policy, Health care	International		Medium-high	No			No
<a href="#">Helsana Versicherungen AG Switzerland</a>		Health Services & Funds	Policy, Health care	National	Switzerland	Medium-high	No			No
<a href="#">HTA Agency Andalusia</a>	AETSA	Authorities and regulatory bodies	Policy, Health care	Regional	Spain, Andalusica	Low-Medium	No			No
<a href="#">HTA Unit in A. Gemelli Teaching Hospital Italy</a>	UVT	Authorities and regulatory bodies	Policy, Health care	National	Italy	Medium-high	No			No
<a href="#">Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Germany</a>	IQWiG	Authorities and regulatory bodies	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">Instituto de Salud Carlos III Spain</a>	ISCIII	Funding Agencies & Entities Supporting Research	Policy, Health care	National	Spain	Medium-high	No			Yes
<a href="#">International Network of Agencies for Health Technology Assessment</a>	INAHTA	Authorities and regulatory bodies	Policy, Health care	International		Medium-high	Yes	Observer, Enabler	Advocate	No
<a href="#">Italian Medicines Agency</a>	AIFA	Authorities and regulatory bodies	Policy, Health care	National	Italy	Medium-high	yes	Observer, Enabler	Advocate	Yes

<a href="#">Italian Society of Food Science and Nutrition</a>	SISA	Professional Associations	Policy, Health care, Nutrition	National	Italy	Medium-high	No			Yes
<a href="#">Magnus Ehrnrooth foundation Finland</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Finland	Medium-high	No			Yes
<a href="#">Maisons sport santé France</a>		Educational Authority	Policy, Health care	National	France	Medium-high	No			No
<a href="#">Ministry of culture, youth and sport Germany</a>		Educational Authority	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">Ministry of Education and Culture Finland</a>		Educational Authority	Policy, Health care	National	Finland	Medium-high	No			Yes
<a href="#">Ministry of Education and Merit Italy</a>		Educational Authority	Policy, Health care	National	Italy	Medium-high	yes	Observer, Enabler	Advocate	Yes
<a href="#">Ministry of Education and Research Estonia</a>		Educational Authority	Policy, Health care	National	Estonia	Medium-high	No			No
<a href="#">Ministry of Education, Training and Sport Spain</a>		Educational Authority	Policy, Health care	National	Spain	Medium-high	No			No
<a href="#">Ministry of Health Italy</a>		Authorities and regulatory bodies	Policy, Health care	National	Italy	Medium-high	Yes	Observer, Enabler	Advocate	Yes
<a href="#">Ministry of Social Affairs and Health Finland</a>		Authorities and regulatory bodies	Policy, Health care	National	Finland	Medium-high	No			No
<a href="#">Ministry of Social Affairs Estonia</a>		Authorities and regulatory bodies	Policy, Health care	National	Estonia	Medium-high	No			No
<a href="#">Mutua Madrileña Foundation Spain</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Spain	Medium-high	No			No

<a href="#">National Health Service Italy</a>	SSN	Health Services & Funds	Policy, Health care	National	Italy	Medium-high	yes	Observer, Enabler	Advocate	Yes
<a href="#">National Institute for Health and Care Excellence UK</a>	NICE	Authorities and regulatory bodies	Policy, Health care	National	UK	Medium-high	No			No
<a href="#">National institute for Value and Technologies in Healthcare Slovak Republic</a>	NIHO	Authorities and regulatory bodies	Policy, Health care	National	Slovak Republic	Medium-high	No			No
<a href="#">NovoNordisk Foundation, Denmark</a>		Professional Associations	Policy, Health care	National	Denmark	Medium-high	yes	Observer, Enabler	Advocate	Yes
<a href="#">ON foundation</a>	ON Foundation	Funding Agencies & Entities Supporting Research	Policy, Health care	International		Medium-high	yes	Observer, Enabler	Advocate	Yes
<a href="#">Ordem dos médicos</a>		Authorities and regulatory bodies	Policy, Health care	National	Portugal	Medium-high	yes	Observer, Enabler	Advocate	Yes
<a href="#">Päivikki and Sakari Sohlberg Foundation Finland</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Finland	Medium-high	yes	Observer, Enabler	Advocate	Yes
<a href="#">Physicians Association for Nutrition Austria</a>	PAN	Professional Associations	Policy, Health care, Nutrition	National	Austria	Medium-high	No			No
<a href="#">Portuguese Association of Nutrition</a>	APN	Professional Associations	Policy, Health care, Nutrition	National	Portugal	Medium-high	No			Yes
<a href="#">Portuguese Association of Public Health Doctors</a>	ANMSP	Professional Associations	Policy, Health care	National	Portugal	Medium-high	No			Yes
<a href="#">Portuguese Ministry of Education</a>		Educational Authority	Policy, Health care	National	Portugal	Medium-high	No			No

<a href="#">Portuguese Ministry of Health</a>		Authorities and regulatory bodies	Policy, Health care	National	Portugal	Medium-high	yes	Observer, Enabler	Advocate	Yes
<a href="#">Regional foundation for biomedical research Italy</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Italy	Medium-high	No			No
<a href="#">Regione Campania</a>		Authorities and regulatory bodies	Policy, Health care	Regional	Spain, Campania	Low-Medium	No			Yes
<a href="#">Research Council of Finland</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Finland	Medium-high	yes	Observer, Enabler	Advocate	Yes
<a href="#">Segurança Social Portugal</a>		Health Services & Funds	Policy, Health care	National	Portugal	Medium-high	No			Yes
<a href="#">Seguridad Social Spain</a>		Health Services & Funds	Policy, Health care	National	Spain	Medium-high	No			No
<a href="#">Social Insurance Institution Finland</a>	Kala	Health Services & Funds	Policy, Health care	National	Finland	Medium-high	No			No
<a href="#">Spanish Agency of Medicines and Medical Devices</a>	AEMPS	Authorities and regulatory bodies	Policy, Health care	National	Spain	Medium-high	No			Yes
<a href="#">Spanish Medical Colleges Organisation</a>	OMC	Professional Associations	Policy, Health care	National	Spain	Medium-high	No			No
<a href="#">Spanish Ministry of Health</a>		Authorities and regulatory bodies	Policy, Health care	National	Spain	Medium-high	No			No
<a href="#">Spanish Ministry of Science, Innovation and Universities</a>	MICINN	Funding Agencies & Entities Supporting Research	Policy, Health care	National	Spain	Medium-high	No			No

<a href="#">Spanish Nutritional Association</a>		Professional Associations	Policy, Health care, Nutrition	National	Spain	Medium-high	No			No
<a href="#">State Secretariat for Education, Research and Innovation Switzerland</a>	SERI	Funding Agencies & Entities Supporting Research	Policy, Health care	National	Switzerland	Medium-high	yes	Observer, Enabler	Advocate	Yes
<a href="#">Swiss Institute for Therapeutic Products</a>	swissmedic	Authorities and regulatory bodies	Policy, Health care	National	Switzerland	Medium-high	No			No
<a href="#">Swiss Medical Association</a>	FMH	Professional Associations	Policy, Health care	National	Switzerland	Medium-high	No			No
<a href="#">Swiss national science foundation</a>	SNSF	Funding Agencies & Entities Supporting Research	Policy, Health care	National	Switzerland	Medium-high	yes	Observer, Enabler	Advocate	No
<a href="#">Swiss Nutrition and Health Foundation</a>	SNH	Professional Associations	Policy, Health care	National	Switzerland	Medium-high	No			No
<a href="#">The Association of Clinical and Public Health Nutritionists in Finland</a>	RTY	Professional Associations	Policy, Health care, Nutrition	National	Finland	Medium-high	No			No
<a href="#">The Austrian Medical Association</a>		Professional Associations	Policy, Health care	National	Austria	Medium-high	No			No
<a href="#">The Federal Department of Economic Affairs, Education and Research Switzerland</a>	EAER	Educational Authority	Policy, Health care	National	Switzerland	Medium-high	No			No
<a href="#">The Federal Joint Committee Germany</a>	G-BA	Authorities and regulatory bodies	Policy, Health care	National	Germany	Medium-high	No			No
<a href="#">The Finnish Medical Society</a>		Funding Agencies & Entities	Policy, Health care	National	Finland	Medium-high	No			No

		Supporting Research								
<a href="#">The Finnish Society of Gastroenterology, Finland</a>		Professional Associations	Policy, Health care, Gastroenterology	National	Finland	Medium-high	No			Yes
<a href="#">The German Nutrition Society</a>	DGE	Professional Associations	Policy, Health care, Nutrition	National	Germany	Medium-high	No			No
<a href="#">The Italian National Agenca for Regional Health Services</a>	AGENAS	Authorities and regulatory bodies	Policy, Health care	National	Italy	Medium-high	Yes	Observer, Enabler	Advocate	Yes
<a href="#">The Netherlands Organisation for Health Research and Development</a>	ZonMW	Authorities and regulatory bodies	Policy, Health care	National	Netherlands	Medium-high	No			No
<a href="#">The Paulo Foundation, Finland</a>		Professional Associations	Policy, Health care	National	Finland	Medium-high	yes	Observer, Enabler	Advocate	Yes
<a href="#">The State Agency of Medicines Estonia</a>		Authorities and regulatory bodies	Policy, Health care	National	Estonia	Medium-high	No			No
<a href="#">U.S. Food and Drug Administration</a>	FDA	Authorities and regulatory bodies	Policy, Health care	National	USA	Medium-high	Yes	Observer, Enabler	Advocate	Yes
<a href="#">Vienna Science and Technology Fund</a>	WWTF	Funding Agencies & Entities Supporting Research	Policy, Health care	Regional	Austria, Vienna	Low-Medium	No			No
<a href="#">Yrjö Jahnsson Foundation Finland</a>		Funding Agencies & Entities Supporting Research	Policy, Health care	National	Finland	Medium-high	No			Yes
<a href="#">Zorginstituut Nederland</a>	ZIN	Authorities and regulatory bodies	Policy, Health care	National	Netherlands	Medium-high	No			No

Industry										
<a href="#">Alfasigma</a>		Pharma Industry	Research, Health Care	International		Medium-high	No			Yes
<a href="#">Andaman7</a>		Service Providers	Digital health solutions, Health Care	International		Medium-High	No			No
<a href="#">optissen</a>		Pharma Industry	Research, RD, Health Care	National	Switzerland	Medium-high	No			No
<a href="#">Artialis</a>		Service Providers	Research, Engineering & Biotechnology, RD	International		Medium-High	No			No
<a href="#">Artificial Intelligence Expert</a>	AIE	Service Providers	AI, Biomarker, Research	International		Medium-High	No			No
<a href="#">ASL Salerno</a>		Service Providers	Research, Health care	Regional	Italy, Campania	Low-Medium	No			No
<a href="#">Asociación de Productores de Aceite e Aceituna de Galicia</a>	APAAG	Industrial Associations	Research, Policy, Digital health solutions	Regional	Spain, Galicia	Low-Medium	No			No
<a href="#">Asociación Española de la Industria y Comercio Exportador de Aceites de Oliva y Aceites de Orujo</a>	ASOLIVA	Industrial Associations	Research, Policy, Digital health solutions	National	Spain	Medium-High	No			No
<a href="#">Association for Accessible Medicine</a>	AAM	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	International		Medium-High	No			No
<a href="#">Association of French ICT SMEs and federations</a>		Industrial Associations	Research, Policy, Digital health solutions	National	France	Medium-High	No			No

<a href="#">Association of Research-Based Pharmaceutical Companies</a>	vfa	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	National	Germany	Medium-High	No			No
<a href="#">Bacthera</a>		Service Providers	Research, Engineering & Biotechnology, Microbiome	International		Medium-High	Yes	Enabler	Advocate, Consult, Collaborate	Yes
<a href="#">Balkan and Black Sea ICT Clusters Network</a>	BBS ICT	Industrial Associations	Research, Policy, Digital health solutions	Regional	Balkan and Black Sea	Low-Medium	No			No
<a href="#">Bio Modeling Systems</a>		Service Providers	Research, Engineering & Biotechnology	International		Medium-High	No			No
<a href="#">BiomimX</a>		Engineering & MedTech	Research, Health Care, Engineering & Biotechnology, Organ-on-a-Chip	International		Medium-High	No			No
<a href="#">Biotechnology Innovation Organisation</a>	Bio	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	International		Medium-High	No			No
<a href="#">Bulgarian Association of Software Companies</a>		Industrial Associations	Research, Policy, Digital health solutions	National	Bulgary	Medium-High	No			No
<a href="#">Bundesverband IT-Mittelstand</a>		Industrial Associations	Research, Policy, Digital health solutions	National	Germany	Medium-High	No			No
<a href="#">CNA Wellbeing and Health</a>	CNA	Industrial Associations	Research, Policy, Digital health solutions	National	Italy	Medium-High	No			No
<a href="#">Colab Trials</a>		Service Providers	Digital health solutions, Health Care,	National	Portugal	Medium-High	No			No

			Clinical trials, Research							
<a href="#">Cooperativas Lácteas Unidas</a>	CLUN	Food Industry	Research, Health Care, Nutrition	National	Spain	Medium-High	No			Yes
<a href="#">Cryptobiotix</a>		Service Providers	Research, Engineering & Biotechnology, Microbiome	International		Medium-High	No			No
<a href="#">CSC – IT Center for Science</a>	CSC	Service Providers	Digital health solutions, Health Care	International		Medium-High	Yes	Enabler	Collaborate, use of service	Yes
<a href="#">Data Colab</a>		Service Providers	Digital health solutions, Health Care	International		Medium-High	No			No
<a href="#">Drug Information Association</a>	DIA	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	International		Medium-High	No			No
<a href="#">EDIH Südwest</a>		Service Providers	Digital health solutions, Health Care	Regional	Germany, Süd-West	Low-Medium	No			Yes
<a href="#">Euformatics OY</a>		Service Providers	Research, Engineering & Biotechnology, Health care	International		Medium-High	No			No
<a href="#">European Digital SME Alliance</a>		Industrial Associations	Research, Policy, Health Care	European		Medium-High	No			No
<a href="#">European Federation of Pharmaceutical Industries and Associations</a>	efpia	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	European		Medium-High	Yes	End User	Advocate, Consult, Collaborate	No
<a href="#">Federación Española de Industriales Fabricantes de Aceite de Oliva</a>	INFAOLIVA	Industrial Associations	Research, Policy, Digital health solutions	National	Spain	Medium-High	Yes	End User	Communicate, Collaborate	No

<a href="#">Fundecyt-pctex</a>		Service Providers	Other	National	Spain	Medium-High	No			No
<a href="#">HAT</a>		Service Providers	Digital health solutions, Health Care	European		Medium-High	No			No
<a href="#">HealthCapital Berlin Brandenburg</a>		Service Providers	Health Care, Policy	Regional	Germany, Berlin-Brandenburg	Low-Medium	No			No
<a href="#">HealthTech Lisboa</a>		Service Providers	Research, Engineering & Biotechnology	National	Portugal	Medium-High	No			No
<a href="#">help doctor</a>		Service Providers	Digital health solutions, Health Care	National	Germany	Medium-High	No			No
<a href="#">Humanized Solutions</a>	HS	Service Providers	Digital health solutions, Health Care	International		Medium-High	No			No
<a href="#">Infineon</a>		Engineering & MedTech	Research, Health Care, Engineering & Biotechnology	International		Medium-high	No			No
<a href="#">Institute of Entrepreneurship Development</a>	iED	Service Providers	Other	European		Medium-High	Yes	End User, Enabler	Advocate, Consult, Collaborate	No
<a href="#">Interlude Biopharma CO</a>		Pharma Industry	Research, Health Care	International		Medium-high	No			Yes
<a href="#">International Flavors and Fragrances</a>	IFF	Service Providers	Research, Engineering & Biotechnology	International		Medium-High	Yes	Enabler	Advocate, Consult, Collaborate	Yes
<a href="#">International society for biological and environmental repositories</a>	ISBER	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	International		Medium-High	No			No

<a href="#">IPPOCRATE</a>		Engineering & MedTech	Research, Health Care, Engineering & Biotechnology	International		Medium-High	No			No
<a href="#">Italian Association of Information Security</a>	CLUSIT	Industrial Associations	Research, Policy, Digital health solutions	National	Italy	Medium-High	No			No
<a href="#">Italian Digital SME Alliance</a>		Industrial Associations	Research, Policy, Digital health solutions	National	Italy	Medium-High	No			No
<a href="#">Johnson &amp; Johnson Innovative Medicine</a>		Pharma Industry	Research, Health Care	International		Medium-high	Yes	End User, Enabler	Advocate, Consult, Collaborate	Yes
<a href="#">kdg</a>		Engineering & MedTech	Research, Health Care, Engineering & Biotechnology, Organ-on-a-Chip	National	Austria	Medium-high	Yes	End User	Advocate, Consult, Collaborate	No
<a href="#">LiCalb</a>		Service Providers	Research	National	Netherlands	Medium-High	No			No
<a href="#">Lilly</a>		Pharma Industry	Research, Health Care	International		Medium-high	Yes	End User, Enabler	Advocate, Consult, Collaborate	Yes
<a href="#">Medicines for Europe</a>		Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	European		Medium-High	Yes	End User	Advocate, Consult, Collaborate	No
<a href="#">Mipih</a>		Engineering & MedTech	Research, Health Care, Engineering & Biotechnology	National	France	Medium-High	No			No
<a href="#">Network of Romanian IT companies</a>		Industrial Associations	Research, Policy, Digital health solutions	National	Romania	Medium-High	No			No

<a href="#">Novartis</a>		Pharma Industry	Research, Health Care	International		Medium-high	Yes	End User	Advocate, Consult, Collaborate	Yes
<a href="#">Novo Nordisk Pharma GmbH</a>		Pharma Industry	Research, Health Care	International		Medium-high	Yes	End User, Enabler	Advocate, Consult, Collaborate	No
<a href="#">Perseus Biomics</a>		Service Providers	Research, Engineering & Biotechnology, Microbiome	International		Medium-High	No			No
<a href="#">promptly health</a>		Service Providers	Research, Digital health solutions, Health Care	International		Medium-High	No			Yes
<a href="#">SHINE2Europe</a>		Service Providers	Other	European		Medium-High	No			No
<a href="#">Silicon Austria Labs GmbH</a>	SAL	Engineering & MedTech	Research, Health Care, Engineering & Biotechnology, Organ-on-a-Chip	Natinal	Austria	Medium-high	No			No
<a href="#">Software Research &amp; Development Consultancy</a>	SRDC	Service Providers	Health Care	International		Medium-High	No			No
<a href="#">Spanish Confederation of Information Technology, Communication and Electronics Companies</a>	CONETIC	Industrial Associations	Research, Policy, Digital health solutions	National	Spain	Medium-High	No			No
<a href="#">Spinner Dynamics</a>		Engineering & MedTech	Research, Health Care, Engineering & Biotechnology	International		Medium-High	No			No
<a href="#">SRDC</a>		Service Providers	Research, Digital health solutions	International		Medium-High	No			No
<a href="#">startup campus germany</a>		Service Providers	Other	National	Germany	Medium-High	No			No

<a href="#">STRATEC SE</a>	STRATEC	Engineering & MedTech	Research, Health Care, Engineering & Biotechnology	International		Medium-High	Yes	End User	Advocate, Consult, Collaborate	No
<a href="#">The Akkermansia Company</a>		Pharma Industry	Research, Health Care, Nutrition, Microbiome	International		Medium-high	Yes	Enabler	Advocate, Consult, Collaborate	Yes
<a href="#">The European Association for Bioindustries</a>	EuropaBio	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	European		Medium-High	Yes	End User	Advocate, Consult, Collaborate	No
<a href="#">The International Federation of Pharmaceutical Manufacturers and Associations</a>	IFPMA	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	International		Medium-High	No			No
<a href="#">The International Society for Pharmaceutical Engineering</a>	ISPE	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	International		Medium-High	No			No
<a href="#">The Pharmaceutical Research and Manufacturers of America</a>	PhRMA	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	National	USA	Medium-High	No			No
<a href="#">Theoreo SRL</a>		Service Providers	Research, Engineering & Biotechnology, Health care	International		Medium-High	No			No
<a href="#">UCB Pharma</a>		Pharma Industry	Research, Health Care	International		Medium-high	Yes	End User, Enabler	Advocate, Consult, Collaborate	Yes
<a href="#">UK Bioindustry Association</a>	BIA	Industrial Associations	Research, Health Care, Engineering & Biotechnology, Policy	Natinal	UK	Medium-High	No			No

<a href="#">Vértice Saúde</a>		Service Providers	Health Care	National	Portugal	Medium-High	No			No
<a href="#">Viteco</a>		Service Providers	Digital health solutions, Health Care	International		Medium-High	No			No
<a href="#">Wörwag Pharma</a>		Pharma Industry	Research, Health Care, Nutrition	International		Medium-high	No			No
<a href="#">Z-Microsystems</a>		Engineering & MedTech	Research, Health Care, Engineering & Biotechnology, Organ-on-a-Chip	International		Medium-High	Yes	End User, Enabler	Advocate, Consult, Collaborate	No